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Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance,
but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic
Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities,
and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention–related bleeding. Two
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meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meet-
ings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of
the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the
pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on
review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to com-
plement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic
approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regi-
mens for patients undergoing percutaneous coronary intervention.
...................................................................................................................................................................................................
Keywords clinical trial protocols as topic • hemorrhage • percutaneous coronary intervention
Abbreviations
ACS acute coronary syndrome
AF atrial fibrillation
ARC Academic Research Consortium
BARC Bleeding Academic Research Consortium
bAVM brain arteriovenous malformation
BMS bare metal stent
CAD coronary artery disease
CKD chronic kidney disease
DAPT dual antiplatelet therapy
DES drug-eluting stent
eGFR estimated glomerular filtration rate
HBR high bleeding risk
HR hazard ratio
ICH intracranial hemorrhage
NIS Nationwide Inpatient Sample
NSAID nonsteroidal anti-inflammatory drug
OAC oral anticoagulant
OR odds ratio
PCI percutaneous coronary intervention
TIA transient ischemic attack
VKA vitamin K antagonist
The evolution of percutaneous coronary intervention (PCI) over
the last 40 years has facilitated treatment of increasingly complex pa-
tient populations. One such population comprises patients at high
bleeding risk (HBR). In early trials of first-generation drug-eluting
stents (DES), the protocol-recommended dual antiplatelet therapy
(DAPT) duration was 3 to 6 months, but as a result of concerns
about late thrombotic events, this was increased to 12 months in
studies initiated after 2006.1 Coinciding with this shift, patients con-
sidered to be at HBR were either excluded from or underrepre-
sented in clinical trials. The accepted practice in such patients was
bare metal stent (BMS) implantation, given that 1 month of DAPT
was considered sufficient at that time. Until recently, even more in-
clusive studies of contemporary DES continued to exclude patients
for whom guideline-recommended DAPT was considered
unsuitable.2,3
Recently, 3 randomized trials comparing DES and BMS with 1
month of DAPT in patients perceived to be at increased bleeding risk
showed superior safety and efficacy with DES.4–6 These reports
quickly generated global attention as an important public health con-
cern given that, as recently as 2014, BMSs were used in 20% of coron-
ary stenting procedures in patients >_65 years of age in the United
States, with 18.2% of BMS recipients having a predicted bleeding risk
of >_5%/y.7
The challenges in defining the optimal management of patients
undergoing PCI at HBR include a paucity of relevant clinical data and
the use of heterogeneous definitions of HBR that limit interpretation,
generalization, and pooling of published data. In 2006, the first
Academic Research Consortium (ARC) provided standardized defi-
nitions of ischemic end points for coronary stent trials, and in 2011,
the Bleeding ARC (BARC) provided bleeding end point definitions,
both of which have gained wide acceptance in clinical study design,
demonstrating the value of consensus-based definitions in the PCI
field.8,9
With this in mind, the aim of the ARC-HBR initiative is to define
HBR in patients undergoing PCI on the basis of a literature review
and clinical consensus with the primary goal of advancing the consist-
ency and quality of data collection and reporting, thereby supporting
organizations tasked with making recommendations for clinical prac-
tice or regulatory decisions.10 To this end, 2 meetings of the ARC-
HBR group were organized by the Cardiovascular European
Research Center (Massy, France) in Washington, DC, in April 2018
and Paris, France, in October 2018. International academic experts;
representatives of the US Food and Drug Administration, the
Japanese Pharmaceuticals and Medical Devices Agency, and a
European Notified Body (DEKRA, Arnhem, the Netherlands); and
observers from the device and pharmaceutical industries attended
(participants are listed in the Appendix in the online-only Data
Supplement).
Contemporary clinical trials of
coronary stents and antiplatelet
therapy: not generalizable to
patients at HBR
Regulatory approval processes for medical devices differ between
jurisdictions.11 In the United States, for example, completed pivotal
randomized trials of investigational DES submitted for US Food and
2 Urban et al.
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..Drug Administration review have been prospective, multicenter
studies with high internal validity, but enrollment has been limited to
highly selected patients and lesions.12–18 Patients considered unsuit-
able for protocol-mandated DAPT duration have been excluded.
Although more recent DES trials have had more liberal enrollment
criteria, per protocol or de facto, they have continued to exclude
patients with advanced renal impairment, prior bleeding, prior recent
stroke, and hematologic abnormalities (Table I in the online-only
Data Supplement).16–18
Many investigator-initiated “all-comer” randomized trials included
some patients at increased bleeding risk.2,19–24 However, only a mi-
nority of screened patients tend to be enrolled, mean patient age is
similar to that in earlier trials, patients unsuitable for long-term DAPT
continue to be systematically excluded, and details on the proportion
of patients taking oral anticoagulation (OAC) or with other bleeding
risk factors are not consistently reported.2,19–24 Thus, despite
broader inclusion criteria, subjects at HBR are still underrepresented
in contemporary studies.
Clinical trials of DAPT strategies after stenting have also excluded
patients at HBR, with reported major bleeding rates at 1 year varying
between 0.3% and 2.8% (Table 1).25–34
Contemporary clinical trials in
patients at increased risk of
bleeding
Three randomized trials investigating short DAPT durations have
been completed in patients undergoing PCI perceived to be at
increased bleeding risk,4–6 and many trials are currently ongoing
(Table II in the online-only Data Supplement). Inclusion criteria in
these trials largely reflect exclusion criteria in prior DES studies of
patients not at HBR receiving different DAPT durations, but there is
significant heterogeneity with respect to the patient populations
included.
Among completed studies, the LEADERS FREE trial (Polymer-free
drug-coated coronary stents in patients at high bleeding risk;
n=2466) was the trial most broadly inclusive of patients at HBR to
date, with a mean of 1.7 bleeding risk criteria per patient.4 The ZEUS
trial (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES
Candidates; n=1606) enrolled uncertain DES candidates on the basis
of criteria for high thrombotic, restenotic, or bleeding risk,35 with a
prespecified subgroup analysis of patients who met criteria for HBR
....................................................................................................................................................................................................................
Table 1 One-year bleeding rates in trials of antiplatelet therapy after coronary stenting
Trial (Year of
Publication)
Patients,
n
Type of
Patients
Inclusion of
Periprocedural
Bleeding
Overall
Bleeding, %
Bleeding
Definition Used
Adjudication of
Bleeding Events
RESET (2012)25 2117 Selected low
bleeding risk
Yes 0.7 TIMI major or minor CEC adjudicated
EXCELLENT (2012)26 1443 Selected low
bleeding risk
Yes 1 TIMI major or minor CEC adjudicated
ARCTIC (2012)27 2440 All comers Yes 2.8 STEEPLE major CEC adjudicated
PRODIGY (2012)28 1970 All comers No (first 30 d
excluded)
2.0† BARC 3 or 5 CEC adjudicated
OPTIMIZE (2013)29 3119 Selected low
bleeding risk
Yes 0.5 Protocol-defined CEC adjudicated
DAPT* (2014)30 22 866 Selected low
bleeding risk
Yes 2.7 GUSTO moderate or severe CEC adjudicated
SECURITY (2014)31 1399 Selected low
bleeding risk
Yes 0.9 BARC 3 or 5 CEC adjudicated
PRECISE-DAPT (2017)32 14 963 Selected low
bleeding risk
No (first 7 d
excluded)
1.5 TIMI major or minor CEC adjudicated
SMART-DATE (2018)34 2712 ACS Yes 0.3† BARC 3 or 5 CEC adjudicated
GLOBAL LEADERS (2018)33 15 968 All comers Yes 1.9† BARC 3 or 5 Site reported
Bleeding definitions are shown in the Appendix in the online-only Data Supplement. ACS indicates acute coronary syndrome; ARCTIC, bedside monitoring to adjust antiplatelet
therapy for coronary stenting; BARC, Bleeding Academic Research Consortium; CEC, Clinical Events Committee; DAPT, Dual Antiplatelet Therapy Trial; EXCELLENT, Efficacy
of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; GLOBAL LEADERS, Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23
months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-
label, randomised superiority trial; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; OPTIMIZE, Optimized
Duration of Clopidogrel Therapy Following Treatment With the Endeavor; PRECISE-DAPT, Predicting Bleeding Complications In Patients Undergoing Stent Implantation and
Subsequent Dual Anti Platelet Therapy; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; RESET, Real Safety and
Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation; SECURITY, Second Generation Drug-Eluting Stents Implantation
Followed by Six Versus Twelve-Month Dual-Antiplatelet Therapy; SMART-DATE, Safety of 6-Month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes;
STEEPLE, Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomized Evaluation; and TIMI, Thrombolysis in Myocardial Infarction.
*First year after enrollment, before randomization.
†One-year bleeding rates were obtained as personal communications from the principal investigators of these 3 trials.
ARC-Defined High Bleeding Risk in PCI Patients 3
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(ZEUS-HBR; n=828).5 The SENIOR trial (Drug-eluting stents in eld-
erly patients with coronary artery disease: a randomized single-blind
trial; n=1200) included elderly patients with no other specified inclu-
sion criteria associated with increased bleeding risk.6 The most fre-
quently met criterion associated with increased bleeding risk in all 3
trials was advanced age (in 64%, 51%, and 100% of patients in
LEADERS FREE, ZEUS-HBR, and SENIOR, respectively), although
the lower cutoff for age differed between trials (>80 years in ZEUS-
HBR versus >_75 years in LEADERS FREE and SENIOR). The second
most frequently met characteristic was indication for OAC in 36%,
38%, and 18% of patients, respectively. Although renal impairment
was the third most commonly met criterion in LEADERS FREE
(19%), it was not a prespecified criterion for HBR status in ZEUS-
HBR. Early planned surgery was a bleeding risk inclusion criterion in
LEADERS FREE (met in 16% of patients), but such patients were
excluded in ZEUS-HBR and SENIOR. Prior hemorrhagic stroke was
also an inclusion criterion in LEADERS FREE but was an exclusion cri-
terion in SENIOR, and although it was not an exclusion criterion in
ZEUS-HBR, no information on its prevalence is provided. Bleeding
rates according to inclusion criteria in LEADERS FREE are shown in
Table III in the online-only Data Supplement.
The differences in eligibility criteria and enrolled patient popula-
tions in completed trials are reflected in the differences in bleeding
event rates. In LEADERS FREE and ZEUS-HBR, the 1-year rates of
BARC 3 to 5 bleeding in patients treated with 1-month DAPT after
PCI were 7.3% and 4.2%, respectively, and in the SENIOR trial, the 1-
year BARC 3 to 5 bleeding rate in patients treated with 1 to 6 months
of DAPT after PCI was3.5%. Such differences highlight the need for
a standardized definition of HBR.
Currently available bleeding risk
scores
At least 6 scores have been developed that predict long-term bleed-
ing risk in patients taking antiplatelet therapy.32,36–39 The 2017
European Society of Cardiology focused update on DAPT in coron-
ary artery disease (CAD) recommended (Class IIb recommendation,
Level of Evidence A) that the use of risk scores such as the PRECISE-
DAPT (Predicting Bleeding Complications In Patients Undergoing
Stent Implantation and Subsequent Dual Anti Platelet Therapy) and
DAPT scores may be considered to guide antiplatelet therapy after
PCI.40
The main features of existing scores are summarized in Table 2,
and the variables in each score are shown in Table IV in the online-
only Data Supplement.32,36–39,41 Advanced age is the only variable
common to all scores, but age cutoffs for increased bleeding risk and
their relative weights vary between risk scores. In addition, although
baseline anemia was found to be one of the strongest independent
predictors of bleeding assessed in PARIS (patterns of non-adherence
to anti-platelet regimens in stented patients), BleeMACS (Bleeding
Complications in an Multicenter Registry of Patients Discharged
With Diagnosis of Acute Coronary Syndrome), the Dutch aspirin
score, and PRECISE-DAPT,32,36–38 it was not assessed in the develop-
ment of the REACH (Reduction of Atherothrombosis for Continued
Health Registry) or DAPT score.39,41 Moreover, definitions of anemia
differed between studies.
Five variables (prior malignancy, congestive heart failure, body
mass index <25 or >_35 kg/m2, hypercholesterolemia, and elevated
white cell count) are present in only 1 score. Furthermore, all scores
omit certain important variables known to be associated with HBR
because their prevalence is low in patients with CAD or those under-
going PCI (eg, severe liver disease, bleeding diatheses, or thrombo-
cytopenia), because they were rarely recorded in the derivation data
sets (eg, history of cancer or prior bleeding, use of nonsteroidal anti-
inflammatory drugs [NSAIDs], or planned surgery), or because collin-
earity with other selected predictors may have overshadowed their
significance.
Such differences in risk prediction scores reflect heterogeneity in
the patient populations studied, the variables assessed (and their defi-
nitions), and the bleeding definitions used in the development
cohorts. At best, these scores have moderate accuracy for predicting
bleeding, with C statistics in the development cohorts ranging from
0.64 to 0.73 (Table 2). Moreover, none of these scores was validated
in HBR patient populations, highlighting the need for standardized
HBR criteria for evaluating such patients.
Defining HBR criteria
HBR is defined as a BARC 3 or 5 bleeding risk of >_4% at 1 year or a
risk of an intracranial hemorrhage (ICH) of >_1% at 1 year. Thus, a
major criterion for ARC-HBR is defined as any criterion that, in isola-
tion, is considered to confer a BARC 3 or 5 bleeding risk of >_4% at 1
year or any criterion considered to be associated with a risk of ICH
of >_1% at 1 year. A minor criterion for ARC-HBR is defined as any
criterion that, in isolation, is considered to confer increased bleeding
risk, with a BARC 3 or 5 bleeding rate of <4% at 1 year.
The cutoff value of 4% for BARC 3 or 5 bleeding was based on
consensus of the participants, taking into account that 1-year major
bleeding rates in trials of DAPT after PCI, which largely excluded
patients at HBR, were <3% (Table 1) and that, in DES trials enrolling
patients at HBR, 1-year BARC 3 to 5 bleeding rates were higher
(7.2% in LEADERS FREE [with 1.7 HBR criteria per patient] and 4.2%
in ZEUS-HBR despite only 1 month of DAPT after PCI) and 3.5% in
the SENIOR trial (in which age >_75 years was the sole inclusion
criterion).
Proposed HBR definition
Twenty clinical criteria were identified as major or minor by consen-
sus, supported by published evidence (Table 3 and Figure). Patients
are considered to be at HBR if at least 1 major or 2 minor criteria are
met. The definition is thus binary. Although it is recognized that the
coexistence of increasing numbers of risk factors for bleeding is asso-
ciated with a stepwise increase in risk of BARC 3 to 5 bleeding,5 suffi-
cient data are not currently available to create a point-based score
that would take into account the relative weight of each HBR criter-
ion. Nonetheless, the presence of increasing numbers of major or
minor criteria in any patient further increases bleeding risk, which
may be considered in clinical decision-making and clinical trial analysis.
The proposed consensus-based definition takes into account the
available evidence for patients at HBR undergoing PCI and is
4 Urban et al.
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Table 3 Major and minor criteria for hbr at the time of PCI
Major Minor
Age >_75 y
Anticipated use of long-term oral anticoagulation*
Severe or end-stage CKD (eGFR <30 mL/min) Moderate CKD (eGFR 30–59 mL/min)
Hemoglobin <11 g/dL Hemoglobin 11–12.9 g/dL for men and 11–11.9 g/dL for women
Spontaneous bleeding requiring hospitalization or transfusion in the past 6 mo or
at any time, if recurrent
Spontaneous bleeding requiring hospitalization or transfusion with-
in the past 12 mo not meeting the major criterion
Moderate or severe baseline thrombocytopenia† (platelet count <100 109/L)
Chronic bleeding diathesis
Liver cirrhosis with portal hypertension
Long-term use of oral NSAIDs or steroids
Active malignancy‡ (excluding nonmelanoma skin cancer) within the past 12 mo
Previous spontaneous ICH (at any time)Previous traumatic ICH within the past
12 moPresence of a bAVMModerate or severe ischemic stroke§ within the
past 6 mo
Any ischemic stroke at any time not meeting the major criterion
Nondeferrable major surgery on DAPT
Recent major surgery or major trauma within 30 d before PCI
bAVM indicates brain arteriovenous malformation; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HBR, high bleeding
risk; ICH, intracranial hemorrhage; NSAID, nonsteroidal anti-inflammatory drug; and PCI, percutaneous coronary intervention.
*This excludes vascular protection doses.42
†Baseline thrombocytopenia is defined as thrombocytopenia before PCI.
‡Active malignancy is defined as diagnosis within 12 months and/or ongoing requirement for treatment (including surgery, chemotherapy, or radiotherapy).
§National Institutes of Health Stroke Scale score >_5.
Figure Factors associated with an increased bleeding risk after percutaneous coronary intervention. bAVM indicates brain arteriovenous malfor-
mation; CNS, central nervous system; DAPT, dual antiplatelet treatment; ICH, intracranial hemorrhage; NSAID, nonsteroidal anti-inflammatory drug;
and OAC, oral anticoagulation.
6 Urban et al.
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pragmatic for application to clinical trials supporting clinical practice
recommendations and regulatory review. The criteria making up the
definition are discussed below. Associated major (preferably BARC 3
or 5) bleeding rates or rates of ICH at 1 year are provided when avail-
able. Factors that were considered but not deemed HBR criteria are
also discussed.
Age
Age >_75 years is considered a minor ARC-HBR criterion (Table 3).
Although elderly patients represent the fastest-growing patient
subgroup undergoing PCI,43,44 they tend to be underrepresented in
randomized trials of DES and DAPT. In the SENIOR trial, which
included patients >_75 years of age (mean age, 81.4±4.2 years) treated
with 1 or 6 months of DAPT after coronary stenting (DES versus
BMS), the 1-year rate of BARC 3 to 5 bleeding was 3.5%. Indeed,
elderly patients undergoing PCI tend to have more comorbidities and
coexisting risk factors for bleeding compared with younger
patients.45 A substudy of elderly patients (>_75 years) enrolled in the
LEADERS FREE trial (n=1564) showed that patients who qualified
for inclusion on the basis of age alone (n=562) had a lower rate of 1-
year BARC 3 to 5 bleeding compared with the overall elderly popula-
tion (3.2% versus 7.8%, respectively).46 Nonetheless, in the develop-
ment cohorts of bleeding risk scores in patients undergoing PCI,
advanced age generally persisted as an independent predictor of
bleeding after adjustment for coexisting bleeding risk fac-
tors.32,38,41,47–51
In a patient-level meta-analysis of 6 randomized trials (n=11 473)
comparing short (<_6 months) and longer (12 months) DAPT dur-
ation after PCI, short DAPT halved the rate of protocol-defined
major bleeding at 1 year in patients >_65 years of age (0.5% versus
1.1%; hazard ratio [HR], 0.46 [95% CI, 0.24–0.88]; P=0.02), without
increasing ischemic events (2.4% versus 3.0%; HR, 0.84 [95% CI,
0.60–1.16]; P=0.2856). In contrast, in younger patients, short DAPT
failed to reduce bleeding (0.3% versus 0.5%; HR, 0.59 [95% CI, 0.26–
1.34]; P=0.21), but ischemic events were significantly increased (2.4%
versus 1.4%; HR, 1.67 [95% CI, 1.14–2.44]; P=0.0082), suggesting dif-
ferential bleeding–ischemic risk profiles in elderly versus younger
patients after PCI.52
In summary, bleeding risk increases with age with some confound-
ing resulting from comorbidities, which tend to accumulate in elderly
patients. With this in mind, it must be acknowledged that biological
age and chronological age may differ. Although the relationship be-
tween age and bleeding risk appears to be continuous, a pragmatic
decision was made to use a binary variable in the current definition.
Oral anticoagulation
The anticipated use of long-term OAC (with a vitamin K antagonist
[VKA] or non–vitamin K OAC) after PCI is considered a major ARC-
HBR criterion (Table 3).
The most common indication for OAC in patients undergoing PCI
is coexisting atrial fibrillation (AF). When treating such patients,
physicians must balance the risk of thromboembolism with AF, the
risk of stent thrombosis and myocardial infarction after PCI, and the
risk of bleeding on combined antithrombotic therapy.53 Bleeding risk
is magnified in the setting of triple antithrombotic therapy (OAC plus
DAPT).54
In the WOEST trial (What Is the Optimal antiplatelet and
Anticoagulant Therapy in Patients With Oral Anticoagulation and
Coronary Stenting; n=573), 1-year rates of BARC 3 to 5 bleeding in
patients on VKAs after PCI were 6.5% and 12.7% in the double (VKA
plus clopidogrel) and triple (VKA plus aspirin and clopidogrel) ther-
apy arms, respectively (HR, 0.49 [95% CI, 0.28–0.86]; P=0.011).55 In
the ISAR-TRIPLE trial (Intracoronary Stenting and Antithrombotic
Regimen-Testing of a 6-Week versus a 6-Month Clopidogrel
Treatment Regimen in Patients with Concomitant Aspirin and Oral
Anticoagulant Therapy Following Drug-Eluting Stenting; n=614),
patients on a VKA undergoing PCI were randomized to treatment
with triple therapy for 6 weeks versus 6 months, with continuation of
VKA and aspirin thereafter.56 At 9 months, rates of BARC 3 to 5
bleeding were 11.1% and 10.4%, respectively, with comparable
bleeding event rates between treatment groups.
In the PIONEER AF-PCI trial (Open-Label, Randomized,
Controlled, Multicenter Study Exploring Two Treatment Strategies
of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist
Treatment Strategy in Subjects With Atrial Fibrillation Who
Undergo Percutaneous Coronary Intervention) and RE-DUAL PCI
trial (Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy
With Warfarin in Patients With AF That Undergo a PCI With
Stenting), patients with AF undergoing PCI were allocated to treat-
ment with dual therapy consisting of a non–vitamin K OAC and a
P2Y12 inhibitor or triple therapy consisting of a VKA, a P2Y12 inhibi-
tor, and aspirin. Although bleeding rates were lower in patients on
dual therapy, it is unclear to what extent this was attributable to the
omission of aspirin as opposed to the use of a non–vitamin K OAC
instead of a VKA.57,58 In PIONEER AF-PCI (n=2124), 1-year BARC 3
to 5 bleeding rates were 4.1% with dual therapy including low-dose
rivaroxaban (15 mg daily), 4.4% with triple therapy including very-
low-dose rivaroxaban (2.5 mg twice daily), and 7.9% with triple ther-
apy including a VKA. In RE-DUAL PCI (n=2725), respective rates of
TIMI (Thrombolysis in Myocardial Infarction) major/minor bleeding
at 14 months were 3.0% versus 7.0% in patients treated with dual
therapy with dabigatran 110 mg twice daily versus triple therapy with
warfarin (HR, 0.41 [95% CI, 0.26–0.63]; P<0.001) and 3.5% versus
6.3% in those treated with dual therapy including dabigatran 150 mg
twice daily versus triple therapy including warfarin (HR, 0.53 [95% CI,
0.33–0.85]; P=0.009). In both trials, bleeding rates in the groups
treated with triple therapy with a VKA were markedly lower than
those observed in WOEST and ISAR-TRIPLE, indicating an overall
lower bleeding risk profile in the populations enrolled, possibly
explained by the stricter patient selection criteria in PIONEER AF-
PCI and RE-DUAL PCI.
Although bleeding risk may differ between VKAs and novel antico-
agulants and between individual novel anticoagulants (Table V in the
online-only Data Supplement) and different doses, exposure times
and variations in renal function may confer differential bleeding risks.
Weighting the relative bleeding risk with different OAC regimens is
beyond the scope of this definition.
Chronic kidney disease
Severe or end-stage chronic kidney disease (CKD; estimated glom-
erular filtration rate [eGFR] <30 mL/min) is considered a major
ARC-HBR criterion, and moderate CKD (eGFR, 30–59 mL/min) is
considered a minor ARC-HBR criterion (Table 3).
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..Approximately 30% of patients undergoing PCI have an eGFR <60
mL/min,59 but patients with severe CKD have generally been
excluded from randomized trials. Even mild CKD is an independent
risk factor for bleeding after PCI,60,61 and the risk increases incremen-
tally with worsening CKD (Table 4).60–64 One mechanism may be
reduced clearance of certain antithrombotic medications. In the
PRECISE-DAPT bleeding risk score,32 eGFR <30 mL/min in isolation
places patients in the highest quartile for bleeding risk, whereas
milder CKD is associated with a slightly to moderately increased
bleeding risk.
The increased bleeding risk with CKD must be considered in the
context of a proportionately increased risk of ischemic events
(Table 4), making this balance more sensitive in patients with CKD
compared with most other HBR criteria. In the DAPT score, a clinical
decision tool to identify patients expected to derive benefit versus
harm from prolonged DAPT after PCI, CKD is not a variable because
the associated bleeding risk was balanced by an almost identical ische-
mic risk.41
From the data presented, the consensus decision was to use CKD
stages rather than eGFR as a continuous variable in the definition
(Table 4).
Anemia
A hemoglobin level <11 g/dL is considered a major ARC-HBR criter-
ion. A hemoglobin level of 11 to 12.9 g/dL for men and 11 to 11.9
g/dL for women is considered a minor ARC-HBR criterion (Table 3).
Anemia defined by World Health Organization criteria (hemoglo-
bin <13 g/dL in men and <12 g/dL in women) is frequently encoun-
tered in patients undergoing PCI, with a reported prevalence of
21.6% in the Bern DES Registry.65 Anemia correlates with the risk of
future bleeding in patients undergoing PCI. The 1-year risk of BARC
3 or 5 bleeding in patients with acute coronary syndrome (ACS)
treated with PCI followed by prasugrel or ticagrelor in the RENAMI
registry (Registry of New Antiplatelets in Patients With Myocardial
Infarction; n=4424) was significantly higher in patients with World
Health Organization–defined anemia compared with those without
(5.4% versus 1.5%, respectively; P=0.001).66 In a meta-analysis of 44
studies including >230 000 patients undergoing PCI, anemia (defined
by World Health Organization criteria in the majority of studies) was
present in 16% of patients and was associated with a 2-fold risk of
subsequent bleeding (as defined in individual studies; adjusted risk
ratio, 2.31 [95% CI, 1.44–3.71]), as well as an increased risk of ische-
mic events and mortality.67 Furthermore, bleeding risk increased
with increasing severity of anemia.
Baseline anemia was also found to be an important predictor of
bleeding in the development cohorts of a number of bleeding risk
scores. In PARIS, baseline anemia (hemoglobin <12 g/dL in men and
<11 g/dL in women) was a strong predictor of 2-year BARC 3 or 5
bleeding (9.5% with versus 2.7% without anemia; adjusted HR, 2.72
[95% CI, 1.83–4.04]; P<0.0001).38 In BleeMACS, hemoglobin <11 g/
dL was the strongest predictor of serious spontaneous bleeding
(defined in the Appendix in the online-only Data Supplement) at 1
year (adjusted HR, 2.41 [95% CI, 1.29–4.50]; P<0.001), and hemoglo-
bin of 11.0 to 13.9 g/dL was also associated with a significantly
increased bleeding risk (adjusted HR, 1.59 [95% CI, 1.14–2.21];
P=0.006) compared with hemoglobin >_14 g/dL.36 In the Dutch
aspirin score, anemia (defined by diagnosis-related groups) was also
found to be one of the most important predictors of a first upper
gastrointestinal bleed on aspirin therapy (adjusted HR, 2.3 [95% CI,
1.9–2.8]; P<0.01).37 In PRECISE-DAPT, each 1-g/dL increase in hemo-
globin between 10 and 12 g/dL was independently associated with a
reduction in the risk of TIMI major/minor bleeding at 1 year (adjusted
HR, 0.67 [95% CI, 0.53–0.84]; P=0.001).32
Prior bleeding and transfusion
Spontaneous (nonintracranial) bleeding requiring hospitalization or
transfusion in the past 6 months (or at any time if recurrent) is con-
sidered a major ARC-HBR criterion, and a first spontaneous (nonin-
tracranial) bleed requiring hospitalization or transfusion >6 and <12
months before PCI is considered a minor ARC-HBR criterion
(Table 3).
Information on the risk of subsequent bleeding in patients with a
prior bleeding event who undergo PCI is scarce. Nonetheless, in the
PRECISE-DAPT score, prior spontaneous bleeding at any time was
found to be an important predictor of future bleeding and, in isola-
tion, places patients in the highest quartile for bleeding risk.32 In
patients (n=320) presenting with peptic ulcer bleeding on aspirin
monotherapy randomized to treatment with clopidogrel versus as-
pirin plus esomeprazole after confirmed ulcer healing, respective 1-
year rates of recurrent ulcer bleeding (defined in the Appendix in the
online-only Data Supplement) were 8.6% versus 0.7% (difference,
7.9% [95% CI, 3.4–12.4]; P=0.001).68 In another randomized trial in
patients (n=153) with acute peptic ulcer bleeding on aspirin mono-
therapy, recurrent ulcer bleeding (defined in the Appendix in the
online-only Data Supplement) at 30 days occurred in 10.3% versus
5.4% of patients allocated to aspirin plus pantoprazole versus aspirin
discontinuation (HR, 1.9 [95% CI, 0.6–6.0]; P=0.25).69
Data on the association between previous blood transfusion and
subsequent bleeding risk in patients undergoing PCI are scarce. In 1
randomized trial of transfusion strategies in patients without PCI with
acute upper gastrointestinal bleeding, patients (n=921) were assigned
to a restrictive (maintain hemoglobin >7 g/dL) or liberal (maintain
hemoglobin >9 g/dL) transfusion strategy. The rate of further in-
hospital bleeding (defined in the Appendix in the online-only Data
Supplement) was significantly lower in patients allocated to the re-
strictive strategy (10% versus 16%; adjusted HR, 0.68 [95% CI, 0.47–
0.98]; P=0.03).70 The highest rates of recurrent bleeding occurred in
the setting of acute blood transfusion, suggesting that the timing of
transfusion appears to an important determinant of bleeding risk.
Bleeding rates at 1 year were not reported.
Thrombocytopenia
Moderate or severe baseline thrombocytopenia (platelet count
<100109/L) is considered a major ARC-HBR criterion (Table 3).
Baseline thrombocytopenia refers to thrombocytopenia that is
present before PCI. This is distinct from acquired thrombocytopenia
after PCI, which results from a postprocedural decline in platelet
count in a patient without baseline thrombocytopenia. Thrombocy-
topenia is classified as mild (100–149109/L), moderate (50–
99109/L), or severe (<50109/L).71 The reported prevalence
of baseline thrombocytopenia in patients undergoing PCI is 2.5%
in the United States and 1.5% in Japan.72,73 Patients with
ARC-Defined High Bleeding Risk in PCI Patients 9
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
thrombocytopenia are underrepresented in randomized trials of
DES and DAPT, and those who are enrolled generally have no more
than mild thrombocytopenia because a platelet count of <100109/
L is a common exclusion criterion.
Thrombocytopenia is a risk factor for both bleeding and ischemic
complications. In an analysis from the US Nationwide Inpatient
Sample (NIS) database, 32 565 patients with chronic thrombocyto-
penia at the time of PCI were propensity-matched with patients with-
out thrombocytopenia.72 The risks of in-hospital postprocedural
bleeding, defined by International Classification of Diseases codes for in-
hospital complications (10.9% versus 4.9%; odds ratio [OR], 2.40
[95% CI, 2.05–2.72]; P<0.0001), and mortality (6.5% versus 2.9%; OR,
2.30 [95% CI, 1.90–2.70]; P<0.0001) were significantly higher in
patients with thrombocytopenia.72 A post hoc analysis of patients
with ST-segment–elevation myocardial infarction treated with PCI in
the HORIZONS-AMI trial (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarction; n=3476)
showed a higher rate of 30-day ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy)-HORIZONS major bleeding
(defined in the Appendix in the online-only Data Supplement) in 146
patients with baseline mild thrombocytopenia compared with those
without thrombocytopenia (15.4% versus 9.1%; P=0.01).74
Bleeding risk appears to be proportional to the degree of
thrombocytopenia. A pooled analysis of 3 Japanese studies including
patients undergoing PCI (n=19 353) showed increased rates of
GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries) moderate/severe bleed-
ing (defined in the Appendix in the online-only Data Supplement) at
3 years in patients with baseline mild thrombocytopenia (9.9% versus
6.9%; adjusted HR, 1.20 [95% CI, 1.03–1.40]; P=0.02) and moderate/
severe thrombocytopenia (23.1% versus 6.9%; adjusted HR, 2.35
[95% CI, 1.80–3.08]; P<0.001) compared with patients without
thrombocytopenia.73
Chronic bleeding diatheses
The presence of a clinically significant chronic bleeding diathesis is
considered a major ARC-HBR criterion (Table 3).
Chronic bleeding diatheses include inherited or acquired condi-
tions known to be associated with increased bleeding risk such as
platelet dysfunction, von Willebrand disease (prevalence of 1%–2% in
the general population), inherited or acquired clotting factor deficien-
cies (including factors VII, VIII [hemophilia A], IX [hemophilia B], and
XI), or acquired antibodies to clotting factors, among others.75–77 For
the purpose of the current HBR definition, thrombocytopenia is dis-
cussed separately.
Data on bleeding rates after PCI in patients with bleeding diatheses
are scarce because such patients are generally excluded from DES
and DAPT trials. In ZEUS-HBR, hematologic disorders or any known
coagulopathy-associated bleeding diathesis (including prior or cur-
rent thrombocytopenia, defined as platelet count <100109/L) was
a criterion conferring HBR status in 95 patients (11.5%).5
Among 796 patients with von Willebrand disease followed up for
1 year, 75 (9.4%) required clotting factor replacement therapy for
232 bleeding events.75 In a series of 54 patients with hemophilia A or
B undergoing coronary angiography or PCI, major periprocedural
bleeding occurred in 3 patients (6%), and 11 patients (20%) had a
bleeding event (predominantly minor) within 1 year.78 The most
important and reliable predictor of bleeding in patients with bleeding
diatheses is a personal history of bleeding, which may be assessed
with a bleeding questionnaire.79 However, given the lack of data and
the low prevalence of such conditions in patients undergoing PCI,
attempting to weight the differential bleeding risks with different
bleeding diatheses and their levels of severity is beyond the scope of
the current definition.
Cirrhosis with portal hypertension
The presence of cirrhosis with portal hypertension is considered a
major ARC-HBR criterion (Table 3).
The reported prevalence of cirrhosis in patients undergoing PCI in
the United States is 1.2%.80 The bleeding risk in chronic liver disease
may be related to impaired hemostasis (resulting from coagulation
factor deficiency, thrombocytopenia, platelet dysfunction, or
increased fibrinolysis)81 or to esophageal varices in the presence of
portal hypertension. Bleeding complications on antithrombotic ther-
apy in such patients are potentially catastrophic.82
Patients with severe liver disease are generally excluded from DES
and DAPT trials. In the LEADERS FREE trial, although severe chronic
liver disease was an inclusion criterion for HBR, <1% of enrolled
patients fulfilled this criterion.4 The finding of obstructive CAD during
transplantation workup in patients with end-stage liver disease is an
increasingly common scenario. A single-center study of patients
(n=1221) who underwent orthotopic liver transplantation over a 10-
year period in the United States reported that 38.6% of patients
underwent coronary angiography and 4.7% underwent PCI before
transplantation, with rates of both increasing over time.83
Data from the NIS registry (n=4 376 950) showed that liver dis-
ease was an independent predictor of in-hospital gastrointestinal
bleeding in patients undergoing PCI (OR, 2.59 [95% CI, 2.22–3.02];
P<0.001).84 In another retrospective study of PCI procedures
(n=1 051 252) in the NIS, 26.0% of patients with cirrhosis had a coa-
gulopathy at baseline, 20.5% had anemia, and 3.9% had a hematologic
or oncological malignancy.80 The in-hospital mortality rate over the
study period (3.6%) was higher compared with historical studies of
the NIS database (0.5%–1.1%), and the most common postproce-
dural complications were hemorrhage (6.6% of patients) and the
need for transfusion (11.3% of patients). In a retrospective study of
patients with cirrhosis and CAD (n=148) treated by either coronary
stenting with DAPT or medical therapy with aspirin monotherapy,
the rate of gastrointestinal bleeding at 1 year was 22% versus 5%, re-
spectively (P=0.003).85 An observational study of patients with
chronic hepatitis B virus (n=1674) showed significantly higher bleed-
ing rates (defined as International Society on Thrombosis and
Haemostasis major bleeding or clinically relevant nonmajor bleed-
ing)86,87 in patients taking antiplatelet therapy compared with those
without antiplatelet therapy (9.5% versus 1.8%; HR, 3.28 [95% CI,
1.98–5.42]; P< 0.001).88 Although Child-Pugh and Mayo End-Stage
Liver Disease criteria are used as exclusion criteria in some DES and
DAPT trials, such scores were validated for predicting mortality in
end-stage liver disease but not for predicting bleeding risk.89–91
Cancer
Active malignancy (excluding nonmelanoma skin cancer) is consid-
ered a major ARC-HBR criterion (Table 3). Active malignancy is
defined as diagnosis within the previous 12 months or ongoing active
10 Urban et al.
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cancer treatment (surgery, radiotherapy, chemotherapy, or immuno-
therapy). Cancer that is considered to be in complete remission or
requires only maintenance therapy (eg, tamoxifen for breast cancer)
is not considered active.
The prevalence of current or previous cancer in patients under-
going PCI in the US NIS database increased from 6.3% in 2004 to
9.5% in 2014.92 Of 6 571 034 patients undergoing PCI, 1.8% had a
current cancer diagnosis and 5.8% had previous cancer. Current can-
cer was associated with higher rates of in-hospital bleeding (defined
by International Classification of Diseases, Ninth Revision, Clinical
Modification codes, shown in the Appendix in the online-only Data
Supplement) compared with previous cancer and no cancer history
(9.7% versus 4.2% versus 3.1%; OR [current versus no cancer], 1.92
[95% CI, 1.82–2.04] and OR [historical versus no cancer], 1.08 [95%
CI, 1.03–1.13]) and ranged between 4.9% and 21.2% according to the
type, site, and spread of the malignancy.92 Bleeding in cancer patients
may be caused by local invasion, by a secondary systemic process, or
by cancer treatment (Table VI in the online-only Data Supplement).
The LEADERS FREE trial included 239 patients (9.7%) with non-
skin cancer diagnosed or treated within 3 years before the index
PCI,4 with 1-year BARC 3 to 5 bleeding in 9.6%. In an observational
study of patients >_65 years of age undergoing PCI (n=22 798), late
bleeding (defined as hospitalization for bleeding <_1 year after dis-
charge) was reported in 5.0% of patients with a history of cancer,
which was an independent predictor of late bleeding (HR, 1.80 [95%
CI, 1.09–2.96]; P=0.02).93
In the TRILOGY ACS trial (Targeted Platelet Inhibition to Clarify the
Optimal Strategy to Medically Manage Acute Coronary Syndromes;
n=9240), cancer incidence and outcomes were prospectively assessed
among patients treated with DAPT (including clopidogrel or prasugrel)
after ACS.94 A new diagnosis of cancer was made in 170 patients
(1.8%), of whom 53.5% permanently discontinued DAPT and 59%
required surgery or chemotherapy. GUSTO severe/life-threatening, or
moderate bleeding occurred substantially more frequently among
those with cancer versus those without (11.2% versus 1.5%).
Previous ischemic stroke or ICH
The presence of a brain arteriovenous malformation (bAVM), previ-
ous ICH at any time, and moderate or severe ischemic stroke
(National Institutes of Health Stroke Scale score >_5 on presentation)
within 6 months before PCI are all considered major ARC-HBR crite-
ria. Ischemic stroke at any time not meeting the major criterion is
considered a minor ARC-HBR criterion (Table 3).
In the SCAAR Registry (Swedish Coronary Angiography and
Angioplasty Registry), 5% to 6% of patients undergoing PCI reported
a prior stroke.95 In the NCDR (National Cardiovascular Data
Registry) Cath-PCI, 12% of enrolled patients had a history of cere-
brovascular disease (defined as prior stroke or carotid stenosis).96
Pivotal DES trials, however, excluded patients with a prior stroke
within 6 months of enrollment (Table I in the online-only Data
Supplement). In trials of DES in patients perceived to be at increased
bleeding risk, the prevalence of prior stroke was low, and bleeding
rates for this subgroup were not reported. In LEADERS FREE, 1.6%
of patients had ischemic stroke within the prior 12 months, and 1.3%
had prior ICH.4 In ZEUS-HBR, prior stroke or transient ischemic at-
tack (TIA) was reported in 8% of patients.5 In the SENIOR trial,8%
of the enrolled population had previous ischemic stroke; prior ICH
was an exclusion criterion.6
Trials of DAPT after ACS have also excluded patients with prior
ICH but not prior ischemic stroke/TIA.97–99 In the TRITON (Trial to
Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel)–TIMI 38 trial, patients with prior
TIA or stroke (>3 months before inclusion) who received aspirin and
prasugrel had higher rates of ischemic and hemorrhagic stroke at 15
months compared with patients without prior TIA/stroke (any stroke
occurred in 6.5% [2.3% ICH] and 0.9% [0.2% ICH], respectively),
resulting in a contraindication for prasugrel use in such patients.99 In
contrast, in patients treated with aspirin and clopidogrel, rates of sub-
sequent stroke did not significantly differ between patients with and
those without prior TIA/stroke (1.2% [0% ICH] and 1.0% [0.3% ICH],
respectively). In the PLATO trial (Platelet Inhibition and Patient
Outcomes; n=18 624), patients with prior TIA/stroke (n=1152,
6.2%) treated with DAPT (including ticagrelor or clopidogrel) after
PCI had significantly higher 1-year rates of ICH compared with those
without prior stroke or TIA (0.8% versus 0.2%; unadjusted HR, 3.95
[95% CI, 1.82–8.55]; P=0.0005), with no significant difference in ICH
rates between treatment groups (0.9% for ticagrelor versus 0.7% for
clopidogrel; HR, 1.00 [95% CI, 0.25–3.99]).100 In the TRA-2P [Trial
to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in
Preventing Heart Attack and Stroke in Patients With
Atherosclerosis]–TIMI-50 trial (n=26 449), patients with prior stroke
2 weeks to 1 year before enrollment (n=5746 [21.7%]) had a signifi-
cantly higher rate of ICH at 3 years with vorapaxar compared with
placebo added to standard antiplatelet therapy (2.4% versus 0.9%;
HR, 2.55 [95% CI, 1.52–4.28]; P<0.001).101 The rates of ICH in
patients without prior stroke were markedly lower in both treatment
groups (0.6% [vorapaxar arm] and 0.4% [placebo arm]; HR, 1.55
[95% CI, 1.00–2.41]; P=0.049).
Rates of non-ICH bleeding do not appear to differ significantly be-
tween patients undergoing PCI with and without previous stroke. In
PRECISE-DAPT, patients with and without prior stroke had similar
rates of TIMI major/minor bleeding (HR, 1.16 [95% CI, 0.54–2.48];
P=0.70).32 In PARIS, rates of BARC 3 or 5 bleeding in patients with
and without previous stroke were also similar (4.1% and 3.5%, re-
spectively; P=0.66).38
Six major randomized trials have investigated potent antiplatelet
therapy for secondary stroke prevention (Table 5).102–107 Three trials
enrolled patients with acute minor stroke or TIA (<12–24 hours;
National Institutes of Health Stroke Scale score <3–5) and showed
no significant difference in ICH rates between patients treated with
either DAPT or ticagrelor and those treated with aspirin monother-
apy for 90 days.102–104 MATCH (Management of Atherothrombosis
With Clopidogrel in High-Risk Patients) and PRoFESS (Prevention
Regimen for Effectively Avoiding Second Strokes) enrolled patients
with recent stroke (<_90–120 days). In both trials, overall rates of
bleeding and primary ICH were higher with DAPT compared with
clopidogrel monotherapy, without a significant reduction in ischemic
events.105,106 The SPS3 trial (Secondary Prevention of Small
Subcortical Strokes) patients also showed significantly higher major
bleeding rates and no significant reduction in recurrent stroke with
DAPT compared with aspirin monotherapy in patients with recent
symptomatic lacunar infarcts (<_180 days).107 However, in contrast to
MATCH and PRoFESS, rates of ICH were comparable between
ARC-Defined High Bleeding Risk in PCI Patients 11
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treatment groups, but mortality rates were significantly higher with
DAPT. In line with these findings, American Stroke Association/
American Heart Association guidelines recommend (Class IIa, Level
of Evidence B-R) that DAPT (aspirin and clopidogrel) initiated within
24 hours can be beneficial for early secondary prevention for a
period of up to 90 days,108 but it is not recommended (Class III, Level
of Evidence A) for routine long-term secondary prevention after
minor stroke or TIA.109
There is a lack of prospective data on DAPT and bleeding risk in
patients with large strokes, prior ICH, and bAVMs. Patients with
bAVMs have a high long-term risk of ICH.110 In a patient-level meta-
analysis of 2525 patients with bAVM, the annual risk of first and recur-
rent ICH was 1.3% (95% CI, 1.0–1.7) and 4.8% (95% CI, 3.9–5.9), re-
spectively.111 In a randomized study of unruptured bAVMs (n=223),
the annual first ICH rate without interventional therapy was 2.0%.112
The incremental risk of ICH in patients with bAVM taking antiplatelet
therapy is not known.
Planned major noncardiac surgery
after PCI
Planned nondeferrable major surgery on DAPT after PCI is consid-
ered a major ARC-HBR criterion (Table 3).
After PCI, up to 17% of patients undergo an invasive diagnostic or
therapeutic procedure within 1 year.113,114 The increased risk of
bleeding in a patient on antiplatelet therapy undergoing major surgery
must be balanced against the potential risks of discontinuing DAPT in
the potentially prothrombotic perioperative setting.113,114 Important
considerations include (1) the temporal relationship between PCI
and surgery, (2) whether the surgery is deferrable, (3) the anticipated
bleeding risk specific to the surgical procedure, and (4) the antici-
pated thrombotic risk as defined by patient, lesion, and procedural
characteristics.
In the POISE-2 trial (Perioperative Ischemic Evaluation 2;
n=10 010), 30-day major bleeding rates (defined in the Appendix in
the online-only Data Supplement) after noncardiac surgery were higher
with aspirin compared with placebo (4.6% versus 3.8%; HR, 1.23 [95%
CI, 1.01–1.49]; P=0.04).115 Although clinical practice guidelines provide
recommendations on perioperative management of antithrombotic
therapy, they do not define the perioperative bleeding risk of different
surgical procedures.116,117 To this end, a number of national multidiscip-
linary expert consensus documents have been published in an effort to
standardize perioperative management of antithrombotic therapy
based on balancing the predicted patient-specific ischemic risk with the
anticipated procedure-specific bleeding risk.118–120
In summary, DAPT at the time of or shortly after surgery increases
bleeding risk. Most elective surgery can be deferred beyond the pro-
posed DAPT duration, and elective PCI is rarely necessary before
elective major surgery. For urgent or nondeferrable surgery, the risk
of stent thrombosis is much higher during the first month after PCI
compared with subsequent months.121,122
PCI after recent major surgery or trauma
Major surgery or major trauma within 30 days before PCI is consid-
ered a major ARC-HBR criterion (Table 3).
The reported incidence of perioperative myocardial infarction
after major noncardiac surgery is as high as 10%, depending on both
patient and procedural characteristics.123 No data are available on
bleeding rates when urgent PCI is required after recent major surgery
or trauma. The bleeding risk of different types of surgery (including
trauma surgery) has been reviewed recently.118
Long-term oral NSAID or steroid use
Long-term steroid or oral NSAID use (defined as planned daily intake
for >_4 d/wk) is considered a minor ARC-HBR criterion (Table 3).
NSAIDs represent the most widely used class of medications
worldwide.124,125 Both oral NSAIDs and steroids are associated with
increased gastrointestinal bleeding risk, which is dose-dependent and
increases with long-term use.126,127 There is a paucity of data on
bleeding risk in patients with long-term oral NSAID or steroid use
after PCI because of underrepresentation or underreporting in
randomized trials. Although long-term NSAID or steroid use was an
inclusion criterion in both LEADERS FREE and ZEUS-HBR, this cri-
terion was met in only 72 patients (2.8%) and 25 patients (3%), re-
spectively.4,5 Moreover, their bleeding rates were not reported.
The risk of upper gastrointestinal bleeding is higher with NSAID
monotherapy compared with aspirin monotherapy, and concomitant
use of NSAIDs and aspirin substantially further increases the
risk.37,128 In the CONCERN trial (n=514), patients with arthritis pre-
senting with upper gastrointestinal bleeding on NSAIDs with a re-
quirement for low-dose aspirin were randomized to celecoxib or
naproxen (plus aspirin and esomeprazole) after confirmed ulcer heal-
ing. Recurrent upper gastrointestinal bleeding (defined in the
Appendix in the online-only Data Supplement) rates were 5.6% and
12.3% at 18 months, respectively (HR, 0.44 [95% CI, 0.23–0.82];
P=0.008).129 In the CLASS study (Celecoxib Long-Term Arthritis
Safety Study; n=8059), patients with arthritis were randomized to
celecoxib or either ibuprofen or diclofenac. In the subgroup of
patients taking aspirin, the rates of symptomatic upper gastrointes-
tinal ulcers or complications (bleeding, perforation, and obstruction)
at 6 months were 4.7% and 6.0%, respectively (P=0.49).130
Special considerations
Frailty
Frailty was not included as a criterion because of the paucity of data
demonstrating a causative role in bleeding in patients undergoing PCI
and the lack of a consensus on how frailty is best assessed.131
Bleeding risk may be increased in the setting of frailty as a result of
more frequent falls, the inability to ambulate without assistance, or
postural hypotension. When frailty was evaluated with a functional
impairment score in the ACTION Registry (Acute Coronary
Treatment and Intervention Outcomes Network), it was found to
correlate with an increased risk of major in-hospital bleeding (defined
in the Appendix in the online-only Data Supplement) in 112 000 eld-
erly patients presenting with acute myocardial infarction undergoing
cardiac catheterization. Major bleeding occurred in 6.4%, 10.3%, and
13.6% of patients with no, mild, and moderate to severe frailty, re-
spectively (mild frailty–adjusted HR, 1.33 [95% CI, 1.23–1.44]; mod-
erate to severe frailty–adjusted HR, 1.40 [95% CI, 1.24–1.58]
compared with the group without frailty).132 The inclusion of
advanced age and coexisting ARC-HBR criteria may account, to
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..some degree, for frailty. Further studies on the impact of frailty on
bleeding risk are encouraged.
Ethnicity
The role of ethnicity in post-PCI bleeding risk has not been fully eluci-
dated. Nonetheless, lower doses of several antithrombotic regimens
are recommended in Asian patients compared with patients in
Europe or the United States because of greater bleeding concerns in
Asians.133,134 Bleeding models developed in Western populations
tend to underestimate bleeding risk in Asian populations.135 In a
patient-level meta-analysis, which pooled 7 randomized trials
(n=16 518; 8605 East Asians, 7913 non-Asians), major bleeding
occurred more frequently in East Asians (0.6% versus 0.3%;
P=0.001), whereas major adverse cardiac events occurred more fre-
quently in non–East Asians (0.8% versus 1.8%; P<0.001),136 suggesting
a differential ischemia/bleeding tradeoff in East Asians and non–East
Asians. Further research is needed in this field.
Acute Coronary Syndromes
Compared with stable patients with CAD, patients with ACS are at
increased thrombotic risk, warranting treatment with more potent,
longer-duration antiplatelet therapy. However, such an approach in-
evitably increases bleeding risk. In a meta-analysis of 3 randomized tri-
als of patients with ACS (n=17 393) undergoing PCI with bivalirudin
or heparin plus a glycoprotein IIb/IIIa inhibitor, the rate of TIMI major/
minor bleeding was 5.3% at 30 days.137 In selected patients with ST-
segment–elevation myocardial infarction at low bleeding risk, re-
spective 1-year rates of non–coronary artery bypass graft TIMI
major/minor bleeding were 4.0% and 3.5% with ticagrelor and clopi-
dogrel in the PLATO trial and 5.1% and 4.7% with prasugrel and clo-
pidogrel in the TRITON-TIMI 38 trial.138,139 Other trials of patients
with ACS with more stringent exclusion criteria have reported 2-
year BARC 3 to 5 bleeding rates as low as 0.5% to 0.8%.34 Given that
the increased bleeding risk in patients with ACS is attributable to the
more aggressive antiplatelet therapy rather than the ACS per se, the
consensus was not to consider ACS an HBR criterion.
DAPT Nonadherence
DAPT nonadherence after PCI is well described. In the PARIS study,
at a time when guidelines recommended >_12 months of DAPT for all
patients after stenting, the rate of DAPT discontinuation was 2.6%,
11.8%, and 19.9% at 30 days, 6 months, and 12 months, respective-
ly.140 In contrast, in trials investigating short DAPT regimens, nonad-
herence to recommended DAPT discontinuation may occur. For
example, in the LEADERS FREE trial, despite a recommended 1-
month DAPT duration, 9% remained on DAPT after 1 month.4 In
the SENIOR trial, 20% of patients remained on DAPT at 12 months,
well beyond the recommended 1 to 6 months.6 In the ZEUS trial, al-
though all patients at HBR were prescribed DAPT for 30 days, 38%
remained on DAPT at 2 months and 25% at 6 months.5,35 Although
DAPT nonadherence may increase the risk of thrombotic complica-
tions, nonadherence with recommended discontinuation may in-
crease bleeding complications.
Regulatory considerations
Studies of patients at HBR have intrinsic public health value and sup-
port the mission of regulatory bodies. Consensus definitions are ne-
cessary to improve the efficiency and predictability of study design
and quality and can assist regulatory decision-making for safe and ef-
fective drugs and devices for patients at HBR in a timely fashion. Sex,
nationality, and ethnic differences in bleeding risk may also be import-
ant considerations in trial design and the interpretation of study out-
comes. This article reflects the consensus views of the ARC-HBR
consortium and does not necessarily represent the practices, policies,
requirements, or recommendations of the US Food and Drug
Administration or the Japanese Pharmaceuticals and Medical Devices
Agency. Furthermore, the recommendations in this document do
not represent a regulatory requirement from either agency.
Although regulators consider it acceptable to propose and justify al-
ternative definitions and HBR criteria, they encourage investigators
to discuss any proposed trial-specific definitions of HBR prospectively
with the relevant regulatory bodies before study initiation.
Limitations
A number of important limitations of the proposed definition must
be acknowledged. First, the chosen cutoff values for 1-year BARC 3
or 5 bleeding (4%) and ICH (1%) are arbitrary, according to the ex-
pert opinion of this group. Second, data on rates of BARC 3 or 5
bleeding or ICH at 1 year were not available for a number of criteria,
in which case justification is based on consensus decision alone.
Third, although the relationship between many criteria and bleeding
is continuous, binary criteria have been used to simplify the definition
and to facilitate its use in trial enrollment. In addition, the differential
bleeding risks associated with the criteria have not been weighted be-
yond major and minor because of a lack of data to support such an
approach. Finally, the definition has not been validated in an inde-
pendent patient data set. To this end, as more data become available,
we anticipate validation and recalibration of this initial set of HBR
criteria.
Conclusions
In keeping with previous ARC initiatives, this ARC-HBR definition
addresses an unmet need by providing a framework for evaluating
treatment options for patients undergoing PCI at increased bleeding
risk. It is expected that consistent use of the consensus definitions
will improve our ability to tailor treatment to individual patient needs
and to stimulate scientific progress, innovation, and quality control
initiatives. We therefore encourage trialists and trial sponsors to con-
sider using ARC-HBR definitions in clinical studies with reporting of
BARC 3 or 5 bleeding rates to allow comprehensive and consistent
assessment of patients at HBR.
The ARC-HBR group is cognizant that defining bleeding risk is the
first step toward understanding the continuum of clinically meaningful
risks and benefits in patients at HBR undergoing PCI. Evaluating and
managing the risk of major bleeding must always be balanced by the
ARC-Defined High Bleeding Risk in PCI Patients 15
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assessment of the thrombotic risk. This balance will be addressed in a
future phase of the ARC-HBR initiative.
Supplementary material
Supplementary material online is available at European Heart Journal
online.
Funding
The ARC-HBR group was entirely funded by multiple industry sponsors.
Sponsors participated as observers in both meetings and were provided
a copy of the document before submission. The contributing
companies were Abbott Vascular, Alvimedica, Amgen, AstraZeneca,
Biosensors, Biotronik, Boston Scientific, Celonova, Chiesi, Cordis,
Daiichi Sankyo, Edwards Lifesciences, Janssen, Medinol, Medtronic,
Orbusneich, Portola, Sanofi, Sinomed, Sahajanand Medical Technologies,
and Terumo.
Conflict of interest: Dr Colleran received financial compensation for
her contribution to the preparation of this document. In accordance with
the ARC charter, none of the other participants received fees or honora-
ria for their participation in the meetings or their contribution to this
document. Dr Urban reports receiving speaker and consulting honoraria
as an individual from Biosensors-Europe, Sinomed, and Terumo; partici-
pating in paid review activities (Clinical End Point Committee, Data Safety
Monitoring Board) for Edward Lifesciences, Terumo, and Abbott
Vascular; and serving as a medical codirector at the Cardiovascular
European Research Center, a contract research organization based in
Massy, France. Dr Mehran reports consultant fees to the institution from
Abbott Laboratories and Spectranetics/Philips/Valcano Corp; consulting
fees from Boston Scientific, Cardiovascular Systems Inc, Medscape,
Siemens Medical Solutions, Regeneron Pharmaceuticals Inc, Roivant
Sciences Inc, and Sanofi; being the spouse of a consultant for Abiomed
and The Medicines Company; research funding to the institution from
AstraZeneca, Bayer, Beth Israel Deaconess Hospital, BMS, CSL Behring,
Eli Lilly and DSI, Medtronic, Novartis Pharmaceuticals, and Orbus Neich;
scientific advisory board fees from PLx Opco Inc, dba PLx Pharma Inc; sci-
entific advisory board fees to the institution from Bristol-Myers Squibb;
executive committee fees from Janssen Pharmaceuticals and Osprey
Medical; speaker engagements for Abbott Laboratories; equity from
Claret Medical and Elixir Medical; and Data Safety Monitoring Board fees
to the institution from Atermark Research Partners. Dr Angiolillo reports
payments, consulting fees, or honoraria from Amgen, Aralez,
AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers
Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PLx
Pharma Inc, Pfizer, Sanofi, and The Medicines Company; fees for participa-
tion in review activities from CeloNova and St. Jude Medical; institutional
grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL
Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani
Chemical Industry Co, Merck, Novartis, Osprey Medical, and Renal
Guard Solutions; and funding from the Scott R. MacKenzie Foundation
and the National Institutes of Health/National Center for Advancing
Translational Sciences Clinical and Translational Science Award to the
University of Florida UL1 TR000064 and National Institutes of Health/
National Human Genome Research Institute U01 HG007269. Dr Byrne
reports lecture fees from B. Braun Melsungen AG, Biotronik, Boston
Scientific, and Micell Technologies and research funding to the institution
from Boston Scientific and Celonova Biosciences. Dr Capodanno reports
personal fees from Abbott Vascular, Bayer, Daiichi Sankyo, Pfizer, and
AstraZeneca. Dr Cutlip reports receiving consultant fees from Celonova
Biosciences and academic salary support from the Baim Institute for
Clinical Research, an academic research organization in Boston, MA. Dr
Eikelboom reports consulting fees and grant support from AstraZeneca,
Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli
Lilly, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis. Dr Gibson
reports being chief executive officer of the Baim Institute for Clinical
Research, in addition to receiving research grant funding from Angel
Medical Corp, Bayer Corp, CSL Behring, Janssen Pharmaceuticals,
Johnson & Johnson Corp, and Portola Pharmaceuticals; consultant fees
from Amarin Pharama, Amgen, Bayer Corp, Boehringer Ingelheim,
Boston Clinical Research Institute, Boston Scientific, Cardiovascular
Research Foundation, CSL Behring, Chiesi, Duke Clinical Research
Institute, Eli Lilly and Company, Gilead Sciences, Inc, Impact Bio LTD,
Janssen Pharmaceuticals, Johnson & Johnson Corp, The Medicines
Company, MedImmune, Medtelligence, Merck & Co, Inc, Microport,
Novo Nordisk, PERT Consortium, Pharma Mar, Portola Pharmaceuticals,
Sanofi, Somahlution, Vereseon Corporation, and Web MD; and royalties
as a contributor from UpToDate in Cardiovascular Medicine. Dr Gregson
reports personal fees from Edwards Lifesciences, MvRX, Amarin Corp,
and BioSensors. Dr Haude reports grant support from Biotronik, Orbus
Neich, AbboF, Medtronic, and Cardiac Dimensions; speaker’s bureau
fees from Biotronik, Orbus Neich, AbboF, Medtronic, Lilly, Philips/
Volcano, and Cardiac Dimensions (Proctor); and consultant fees from
Biotronik, Orbus Neich, and AbboF. Dr James reports institutional re-
search grants from AstraZeneca, Bayer, Jansen, The Medicines Company,
Abbot Vascular, and Boston Scientific, as well as honoraria from
AstraZeneca, Bayer, and Medtronic. Dr Kimura reports consulting fees
or honoraria from Abbott Vascular Japan Co, Ltd, Kowa Co, Ltd, Kowa
Pharmaceutical Co Ltd, Sanofi K.K., Nippon Boehringer Ingelheim Co,
Ltd, and Bristol-Myers Squibb K.K., as well as grant support from Otsuka
Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Mitsubishi Tanabe
Pharma Corp, Takeda Pharmaceutical Co Ltd, and Nippon Boehringer
Ingelheim Co, Ltd. Dr Leon reports receiving research grants from
Abbott Vascular, Boston Scientific, Medtronic, Biosensors, and
SinomedEquity-Medinol. Dr Mylotte reports speaker fees from
Biosensors and institutional research grants from Biosensors and
Medtronic. Dr Pocock has served on steering committees or data moni-
toring committees for trials sponsored by AstraZeneca, Bayer,
Boehringer Ingelheim, Boston Scientific, Idorsia, Janssen, Medtronic,
Novartis, Novo Nordisk, and Vifor, and has received grant funding from
AstraZeneca and Merck. Dr Price reports receiving consulting honoraria
from AstraZeneca, Chiesi USA, Medtronic, Boston Scientific, and Abbott
Vascular/St Jude Medical; speaker’s bureau/fees from AstraZeneca, Chiesi
USA, Medtronic, Boston Scientific, Abbott Vascular/St Jude Medical, and
ACIST Medical; and institutional research grants from Daiichi-Sankyo. Dr
Valgimigli reports grants and personal fees from Abbott, AstraZeneca,
and Terumo; personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen,
Alvimedica, Biosensors, and Idorsia; and grants from Medicure. Dr
Varenne reports receiving consulting and research grants from Boston
Scientific, Abbott Vascular, AstraZeneca, and Servier. Dr Yeh reports
consulting and research grants from Abbott Vascular and Boston
Scientific, research grants from Abiomed and AstraZeneca, and consult-
ing fees from Biosense Webster, Medtronic, and Teleflex. Dr Krucoff
reports receiving consulting and research grants from Abbott Vascular,
Biosensors, Boston Scientific, Cook Medical, Medtronic, and
OrbusNeich. Dr Morice is the chief executive officer of the
Cardiovascular European Research Center, the contract research organ-
ization organizing the ARC-HBR initiative. The other authors report no
conflicts.
16 Urban et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
References
1. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams
DO, Feldman TE, Kern MJ, O’Neill WW, Schaff HV, Whitlow PL, Adams CD,
Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA,
Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B,
Tarkington LG, Yancy CW; 2005 WRITING COMMITTEE MEMBERS. 2007
Focused update of the ACC/AHA/SCAI 2005 guideline update for percutan-
eous coronary intervention: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines: 2007 Writing
Group to Review New Evidence and Update the ACC/AHA/SCAI 2005
Guideline Update for Percutaneous Coronary Intervention, writing on behalf of
the 2005 Writing Committee. Circulation. 2008;117:261–295. doi: 10.1161/
CIRCULATIONAHA.107.188208
2. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K,
Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C,
Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Ju¨ni P. Biolimus-elut-
ing stent with biodegradable polymer versus sirolimus-eluting stent with dur-
able polymer for coronary revascularisation (LEADERS): a randomised non-
inferiority trial. Lancet. 2008;372:1163–1173. doi: 10.1016/S0140-6736(08)
61244-1
3. Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi
W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O,
Zhao W, Sudhir K, Hermiller JB. A new era of prospective real-world safety
evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting
Coronary Stent System condition-of-approval post-market study). JACC
Cardiovasc Interv. 2011;4:1298–1309. doi: 10.1016/j.jcin.2011.08.010
4. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie´ D, Naber C, Lipiecki J,
Richardt G, I~niguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland
J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll
HP, Morice MC; LEADERS FREE Investigators. Polymer-free drug-coated cor-
onary stents in patients at high bleeding risk. N Engl J Med. 2015;373:
2038–2047. doi: 10.1056/NEJMoa1503943
5. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S,
Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo
R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M; ZEUS
Investigators. Is bare-metal stent implantation still justifiable in high bleeding risk
patients undergoing percutaneous coronary intervention? A pre-specified ana-
lysis from the ZEUS trial. JACC Cardiovasc Interv. 2016;9:426–436. doi:
10.1016/j.jcin.2015.11.015
6. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie´ D, Hovasse T, Garot
P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-
Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M,
Morice MC, Sinnaeve PR; SENIOR Investigators. Drug-eluting stents in elderly
patients with coronary artery disease (SENIOR): a randomised single-blind trial.
Lancet. 2018;391:41–50. doi: 10.1016/S0140-6736(17)32713-7
7. Rymer JA, Harrison RW, Dai D, Roe MT, Messenger JC, Anderson HV,
Peterson ED and Wang TY. Trends in bare-metal stent use in the United States
in patients aged >/=65 years (from the CathPCI Registry). Am J Cardiol. 2016;
118:959–966.
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG,
Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW,
Serruys PW; Academic Research Consortium. Clinical end points in coronary
stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351.
doi: 10.1161/CIRCULATIONAHA.106.685313
9. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S,
Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P,
Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H.
Standardized bleeding definitions for cardiovascular clinical trials: a consensus
report from the Bleeding Academic Research Consortium. Circulation. 2011;
123:2736–2747. doi: 10.1161/CIRCULATIONAHA.110.009449
10. Krucoff MW, Mehran R, van Es GA, Boam AB, Cutlip DE. The Academic
Research Consortium governance charter. JACC Cardiovasc Interv. 2011;4:
595–596. doi: 10.1016/j.jcin.2011.03.008
11. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M,
Oktay S, Ju¨ni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S.
Report of a European Society of Cardiology-European Association of
Percutaneous Cardiovascular Interventions task force on the evaluation of cor-
onary stents in Europe: executive summary. Eur Heart J. 2015;36:2608–2620.
doi: 10.1093/eurheartj/ehv203
12. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mu¨nzel T, Popma JJ,
Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized,
double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphor-
ylcholine-encapsulated stent for treatment of native coronary artery lesions:
clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;
114:798–806. doi: 10.1161/CIRCULATIONAHA.105.591206
13. Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, Popma JJ,
Fitzgerald PJ, Cutlip DE, Massaro JM, Mauri L; RESOLUTE US Investigators.
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in
the treatment of de novo lesions in native coronary arteries: the RESOLUTE
US clinical trial. J Am Coll Cardiol. 2011;57:1778–1783. doi: 10.1016/j.jacc.
2011.03.005
14. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N,
Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III
Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting
stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;
299:1903–1913. doi: 10.1001/jama.299.16.1903
15. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J,
Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A pro-
spective, randomized evaluation of a novel everolimus-eluting coronary stent:
the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an
Everolimus-Eluting Coronary Stent System [PROMUS Element] for the
Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll
Cardiol. 2011;57:1700–1708. doi: 10.1016/j.jacc.2011.02.016
16. Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ,
Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco
DJ, Dawkins KD. Efficacy and safety of a novel bioabsorbable polymer-coated,
everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ
Cardiovasc Interv. 2015;8:e002372.
17. Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas
M, Kornowski R, Bagur R, Iniguez A, Danenberg H, Feldman R, Jauhar R,
Chandna H, Parikh M, Perlman GY, Balcells M, Markham P, Ozan MO,
Genereux P, Edelman ER, Leon MB, Stone GW. Randomized comparison of
ridaforolimus- and zotarolimus-eluting coronary stents in patients with coron-
ary artery disease: primary results from the BIONICS Trial (BioNIR
Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). Circulation.
2017;136:1304–1314. doi: 10.1161/CIRCULATIONAHA.117.028885
18. Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM,
Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V
Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus
thin, durable polymer everolimus-eluting stents in patients undergoing coronary
revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:
1843–1852. doi: 10.1016/S0140-6736(17)32249-3
19. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz
S, Pache J, Fusaro M, Seyfarth M, Scho¨mig A, Mehilli J; Intracoronary Stenting
and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4)
Investigators. Randomized, non-inferiority trial of three limus agent-eluting
stents with different polymer coatings: the Intracoronary Stenting and
Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4)
Trial. Eur Heart J. 2009;30:2441–2449. doi: 10.1093/eurheartj/ehp352
20. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek
H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P,
DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J,
Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison
of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med.
2010;363:136–146. doi: 10.1056/NEJMoa1004130
21. Park KW, Kang SH, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin
ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW,
Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS; HOST–
ASSURE Investigators. A randomized comparison of platinum chromium-based
everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting
stents in all-comers receiving percutaneous coronary intervention: HOST-
ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery
Stenosis-Safety & Effectiveness of Drug-Eluting Stents & antI-Platelet Regimen),
a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2014;63(pt A):
2805–2816. doi: 10.1016/j.jacc.2014.04.013
22. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH,
Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR,
Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE,
Madsen M, Johnsen SP, Jensen LO, Sørensen HT, Thuesen L, Lassen JF; SORT
OUT III Study Group. Efficacy and safety of zotarolimus-eluting and sirolimus-
eluting coronary stents in routine clinical care (SORT OUT III): a randomised
controlled superiority trial. Lancet. 2010;375:1090–1099. doi: 10.1016/S0
140-6736(10)60208-5
23. von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE,
Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF,
Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J,
Doggen CJM, Lo¨wik MM. Very thin strut biodegradable polymer everolimus-
eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting
stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm,
randomised, non-inferiority trial. Lancet. 2016;388:2607–2617. doi:
10.1016/S0140-6736(16)31920-1
ARC-Defined High Bleeding Risk in PCI Patients 17
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
24. Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nyga˚rd O, Nilsen
DW, Kløw NE, Uchto M, Trovik T, Bendz B, Stavnes S, Bjørnerheim R, Larsen
AI, Slette M, Steigen T, Jakobsen OJ, Bleie Ø, Fossum E, Hanssen TA, Dahl-
Eriksen Ø, Njølstad I, Rasmussen K, Wilsgaard T, Nordrehaug JE;
NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary ar-
tery disease. N Engl J Med. 2016;375:1242–1252. doi: 10.1056/NEJMoa
1607991
25. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park
BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y; RESET
Investigators. A new strategy for discontinuation of dual antiplatelet therapy:
the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy
following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol.
2012;60:1340–1348. doi: 10.1016/j.jacc.2012.06.043
26. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH,
Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY,
Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK,
Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after im-
plantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher
to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter
study. Circulation. 2012;125:505–513. doi: 10.1161/CIRCULATIONAHA.111.
059022
27. Collet JP, Cuisset T, Range´ G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff
P, Carrie´ D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monse´gu J,
Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthe´le´my O,
Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside
monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med.
2012;367:2100–2109. doi: 10.1056/NEJMoa1209979
28. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota
F, Colombo F, Tebaldi M, Fuca` G, Kubbajeh M, Cangiano E, Minarelli M, Scalone
A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R;
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration
of dual-antiplatelet therapy after coronary stenting: a randomized multicenter
trial. Circulation. 2012;125:2015–2026. doi: 10.1161/CIRCULATIONAHA.111.
071589
29. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB
3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr,
Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusm~ao M,
Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial
Investigators. Three vs twelve months of dual antiplatelet therapy after
zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:
2510–2522. doi: 10.1001/jama.2013.282183
30. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW,
Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow
TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30
months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med.
2014;371:2155–2166. doi: 10.1056/NEJMoa1409312
31. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N,
Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E,
Mauri J, Cesana BM, Giustino G, Sardella G. Second-generation drug-eluting
stent implantation followed by 6- versus 12-month dual antiplatelet therapy:
the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–2097.
doi: 10.1016/j.jacc.2014.09.008
32. Costa F, van Klaveren D, James S, Heg D, Ra¨ber L, Feres F, Pilgrim T, Hong MK,
Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL,
Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study
Investigators. Derivation and validation of the predicting bleeding complications
in patients undergoing stent implantation and subsequent dual antiplatelet ther-
apy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets
from clinical trials. Lancet. 2017;389:1025–1034. doi: 10.1016/S0140-
6736(17)30397-5
33. Vranckx P, Valgimigli M, Ju¨ni P, Hamm C, Steg PG, Heg D, van Es GA,
McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Mo¨llmann H,
Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns
RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS
Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor mono-
therapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,
followed by aspirin monotherapy for 12 months after implantation of a drug-
eluting stent: a multicentre, open-label, randomised superiority trial. Lancet.
2018;392:940–949. doi: 10.1016/S0140-6736(18)31858-0
34. Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH,
Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J,
Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC; SMART-
DATE Investigators. 6-Month versus 12-month or longer dual antiplatelet ther-
apy after percutaneous coronary intervention in patients with acute coronary
syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Lancet. 2018;391:1274–1284. doi: 10.1016/S0140-6736(18)30493-8
35. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G,
Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga
E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P,
Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in
uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–815. doi:
10.1016/j.jacc.2014.11.053
36. Raposeiras-Roubı´n S, Faxe´n J, I´~niguez-Romo A, Henriques JPS, D’Ascenzo F,
Saucedo J, Szummer K, Jernberg T, James SK, Juanatey JRG, Wilton SB, Kikkert
WJ, Nu~nez-Gil I, Ariza-Sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T,
Moretti C, Huczek Z, Nie SP, Fujii T, Correia L, Kawashiri MA, Caneiro-Queija
B, Cobas-Paz R, Acu~na JMG, Southern D, Alfonso E, Terol B, Garay A, Zhang
D, Chen Y, Xanthopoulou I, Osman N, Mo¨llmann H, Shiomi H, Giordana F,
Gaita F, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahayshi T,
Sakata K, Yamagishi M, Kalpak O, Kedev S, Rivera-Asenjo D, Abu-Assi E.
Development and external validation of a post-discharge bleeding risk score in
patients with acute coronary syndrome: the BleeMACS score. Int J Cardiol.
2018;254:10–15. doi: 10.1016/j.ijcard.2017.10.103
37. de Groot NL, Hagenaars MP, Smeets HM, Steyerberg EW, Siersema PD, van
Oijen MG. Primary non-variceal upper gastrointestinal bleeding in NSAID and
low-dose aspirin users: development and validation of risk scores for either
medication in two large Dutch cohorts. J Gastroenterol. 2014;49:245–253. doi:
10.1007/s00535-013-0817-y
38. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C,
Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ,
Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg
PG, Pocock S. Coronary thrombosis and major bleeding after PCI with drug-
eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–2234.
doi: 10.1016/j.jacc.2016.02.064
39. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, Ohman
EM, Brennan DM, D’Agostino RB, Bhatt DL, Steg PG; REACH Investigators.
Risk score to predict serious bleeding in stable outpatients with or at risk of
atherothrombosis. Eur Heart J. 2010;31:1257–1265. doi: 10.1093/eurheartj/
ehq021
40. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Ju¨ni P, Kastrati
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG,
Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC
Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.
2017 ESC focused update on dual antiplatelet therapy in coronary artery dis-
ease developed in collaboration with EACTS: the Task Force for dual antiplate-
let therapy in coronary artery disease of the European Society of Cardiology
(ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J. 2018;39:213–260. doi: 10.1093/eurheartj/ehx419
41. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ,
Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese
PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and
validation of a prediction rule for benefit and harm of dual antiplatelet therapy
beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:
1735–1749. doi: 10.1001/jama.2016.3775
42. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O,
Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas
LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-
Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G,
Sto¨rk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ,
Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM,
Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz
F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or
without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:
1319–1330. doi: 10.1056/NEJMoa1709118
43. Gerber Y, Rihal CS, Sundt TM 3rd, Killian JM, Weston SA, Therneau TM, Roger
VL. Coronary revascularization in the community: a population-based study,
1990 to 2004. J Am Coll Cardiol. 2007;50:1223–1229. doi: 10.1016/j.jacc.
2007.06.022
44. Masoudi FA, Ponirakis A, de Lemos JA, Jollis JG, Kremers M, Messenger JC,
Moore JWM, Moussa I, Oetgen WJ, Varosy PD, Vincent RN, Wei J, Curtis JP,
Roe MT, Spertus JA. Trends in U.S. cardiovascular care: 2016 report from 4
ACC national cardiovascular data registries. J Am Coll Cardiol. 2017;69:
1427–1450. doi: 10.1016/j.jacc.2016.12.005
45. Feldman DN, Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong SC,
Minutello RM; New York State Angioplasty Registry. Comparison of outcomes
of percutaneous coronary interventions in patients of three age groups (<60,
60 to 80, and >80 years) (from the New York State Angioplasty Registry). Am J
Cardiol. 2006;98:1334–1339. doi: 10.1016/j.amjcard.2006.06.026
46. Morice MC, Talwar S, Gaemperli O, Richardt G, Eberli F, Meredith I, Zaman A,
Fajadet J, Copt S, Greene S, Urban P. Drug-coated versus bare-metal stents for
18 Urban et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
elderly patients: a predefined sub-study of the LEADERS FREE trial. Int J Cardiol.
2017;243:110–115. doi: 10.1016/j.ijcard.2017.04.079
47. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY,
Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP.
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarc-
tion: the CRUSADE (Can Rapid risk stratification of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the ACC/AHA
Guidelines) Bleeding Score. Circulation. 2009;119:1873–1882.
48. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H,
Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G,
Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute
coronary syndromes. J Am Coll Cardiol. 2010;55:2556–2566. doi: 10.1016/
j.jacc.2009.09.076
49. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon
CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-
elevation and non-ST-elevation myocardial infarction care: derivation and valid-
ation of a model from the ACTION Registry(R)-GWTG. Am J Cardiol. 2011;
107:1136–1143.
50. Rao SV, McCoy LA, Spertus JA, Krone RJ, Singh M, Fitzgerald S, Peterson ED.
An updated bleeding model to predict the risk of post-procedure bleeding
among patients undergoing percutaneous coronary intervention: a report using
an expanded bleeding definition from the National Cardiovascular Data
Registry CathPCI Registry. JACC Cardiovasc Interv. 2013;6:897–904.
51. Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA,
Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H.
Personalising the decision for prolonged dual antiplatelet therapy: development,
validation and potential impact of prognostic models for cardiovascular events
and bleeding in myocardial infarction survivors. Eur Heart J. 2017;38:1048–1055.
doi: 10.1093/eurheartj/ehw683
52. Lee SY, Hong MK, Palmerini T, Kim HS, Valgimigli M, Feres F, Colombo A,
Gilard M, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Stone GW. Short-
term versus long-term dual antiplatelet therapy after drug-eluting stent implant-
ation in elderly patients: a meta-analysis of individual participant data
from 6 randomized trials. JACC Cardiovasc Interv. 2018;11:435–443. doi:
10.1016/j.jcin.2017.10.015
53. Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant ther-
apy in patients with atrial fibrillation in the setting of acute coronary syndromes
or percutaneous coronary interventions. Circ Cardiovasc Interv. 2014;7:113–124.
doi: 10.1161/CIRCINTERVENTIONS.113.001150
54. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ,
Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon
DP. Antithrombotic therapy in patients with atrial fibrillation treated with oral
anticoagulation undergoing percutaneous coronary intervention. Circulation.
2018;138:527–536. doi: 10.1161/CIRCULATIONAHA.118.034722
55. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ‘t Hof AW,
ten Berg JM; WOEST Study Investigators. Use of clopidogrel with or without
aspirin in patients taking oral anticoagulant therapy and undergoing percutan-
eous coronary intervention: an open-label, randomised, controlled trial. Lancet.
2013;381:1107–1115. doi: 10.1016/S0140-6736(12)62177-1
56. Fiedler KA, Maeng M, Mehilli J, Schulz-Schu¨pke S, Byrne RA, Sibbing D,
Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg
S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy
in patients requiring oral anticoagulation after drug-eluting stent implantation:
the ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619–1629. doi:
10.1016/j.jacc.2015.02.050
57. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY,
Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients
with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
58. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M,
Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J,
Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering
Committee and Investigators. Dual antithrombotic therapy with dabigatran after
PCI in atrial fibrillation. N Engl J Med. 2017;377:1513–1524. doi:
10.1056/NEJMoa1708454
59. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod
M, Amin AP, Weintraub WS, Curtis JP, Messenger JC, Rumsfeld JS, Spertus JA.
Validated contemporary risk model of acute kidney injury in patients under-
going percutaneous coronary interventions: insights from the National
Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc. 2014;3:
e001380. doi: 10.1161/JAHA.114.001380
60. Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S,
Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone
GW. Impact of chronic kidney disease on early (30-day) and late (1-year) out-
comes of patients with acute coronary syndromes treated with alternative
antithrombotic treatment strategies: an ACUITY (Acute Catheterization and
Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009;2:
748–757. doi: 10.1016/j.jcin.2009.05.018
61. Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G,
Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC,
Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-term impact of chronic kid-
ney disease in patients with ST-segment elevation myocardial infarction treated
with primary percutaneous coronary intervention: the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial. JACC Cardiovasc Interv. 2011;4:1011–1019. doi:
10.1016/j.jcin.2011.06.012
62. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ,
Nassif D, Lopez JJ, Saucedo JF; EVENT Investigators. In-hospital and 1-year out-
comes among percutaneous coronary intervention patients with chronic kidney
disease in the era of drug-eluting stents: a report from the EVENT (Evaluation
of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv.
2009;2:37–45. doi: 10.1016/j.jcin.2008.06.012
63. Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg
PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ,
Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ,
Colombo A, Mehran R. Incidence, patterns, and impact of dual antiplatelet
therapy cessation among patients with and without chronic kidney disease
undergoing percutaneous coronary intervention: results from the PARIS
Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented
Patients). Circ Cardiovasc Interv. 2018;11:e006144. doi: 10.1161/CIRCINTER
VENTIONS.117.006144
64. Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A,
Witzenbichler B, Weisz G, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy
PL, Mazzaferri EL Jr, Xu K, Parise H, Brodie BR, Stuckey TD, Stone GW.
Prevalence and impact of high platelet reactivity in chronic kidney disease:
results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting
Stents registry. Circ Cardiovasc Interv. 2015;8:e001683. doi: 10.1161/CIRCINT
ERVENTIONS.115.001683
65. Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Ra¨ber L, Stortecky S, Gloekler S,
Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen
M, Meier B, Ju¨ni P, Windecker S. The impact of anemia on long-term clinical
outcome in patients undergoing revascularization with the unrestricted use of
drug-eluting stents. Circ Cardiovasc Interv. 2012;5:202–210. doi:
10.1161/CIRCINTERVENTIONS.111.965749
66. Guerrero C, Garay A, Ariza-Sole´ A, Formiga F, Raposeiras-Roubı´n S, Abu-Assi
E, D’Ascenzo F, Kinnaird T, Manzano-Ferna´ndez S, Alegre O, Sa´nchez-Salado
JC, Lorente V, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A,
Boccuzzi G, Omede` P, Montabone A, Taha S, Durante A, Gili S, Magnani G,
Conrotto F, Bertaina M, Autelli M, Grosso A, Blanco PF, Quadri G, Varbella F,
Tomassini F, Queija BC, Paz RC, Ferna´ndez MC, Pousa IM, Gallo D, Morbiducci
U, Dominguez-Rodriguez A, Valde´s M, Alexopoulos D, I~niguez-Romo A, Gaita
F, Cequier A´. Anemia in patients with acute coronary syndromes treated with
prasugrel or ticagrelor: insights from the RENAMI registry. Thromb Res. 2018;
167:142–148. doi: 10.1016/j.thromres.2018.05.024
67. Kwok CS, Tiong D, Pradhan A, Andreou AY, Nolan J, Bertrand OF, Curzen
N, Urban P, Myint PK, Zaman AG, Loke YK, Mamas MA. Meta-analysis of the
prognostic impact of anemia in patients undergoing percutaneous coronary
intervention. Am J Cardiol. 2016;118:610–620. doi: 10.1016/j.amjcard.2016.
05.059
68. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC,
Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung
JJ. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer
bleeding. N Engl J Med. 2005;352:238–244. doi: 10.1056/NEJMoa042087
69. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW,
Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a
randomized trial. Ann Intern Med. 2010;152:1–9. doi: 10.7326/0003-4819-152-
1-201001050-00179
70. Villanueva C, Colomo A, Bosch A, Concepcio´n M, Hernandez-Gea V, Aracil C,
Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santalo´
M, Mu~niz E, Guarner C. Transfusion strategies for acute upper gastrointestinal
bleeding. N Engl J Med. 2013;368:11–21. doi: 10.1056/NEJMoa1211801
71. McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in
acute coronary syndrome patients with thrombocytopenia: a clinical conun-
drum. Eur Heart J. 2017;38:3488–3492. doi: 10.1093/eurheartj/ehx531
72. Ayoub K, Marji M, Ogunbayo G, Masri A, Abdel-Latif A, Ziada K, Vallurupalli S.
Impact of chronic thrombocytopenia on in-hospital outcomes after percutan-
eous coronary intervention. JACC Cardiovasc Interv. 2018;11:1862–1868. doi:
10.1016/j.jcin.2018.05.033
73. Ito S, Watanabe H, Morimoto T, Yoshikawa Y, Shiomi H, Shizuta S, Ono K,
Yamaji K, Soga Y, Hyodo M, Shirai S, Ando K, Horiuchi H, Kimura T. Impact of
baseline thrombocytopenia on bleeding and mortality after percutaneous
ARC-Defined High Bleeding Risk in PCI Patients 19
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
coronary intervention. Am J Cardiol. 2018;121:1304–1314. doi: 10.1016/
j.amjcard.2018.02.010
74. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen
B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, Stone
GW. Impact of baseline thrombocytopenia on the early and late outcomes after
ST-elevation myocardial infarction treated with primary angioplasty: analysis
from the Harmonizing Outcomes with Revascularization and Stents in Acute
Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161:391–396.
doi: 10.1016/j.ahj.2010.11.001
75. de Raucourt E, Roussel-Robert V, Zetterberg E. Prevention and treatment of
atherosclerosis in haemophilia: how to balance risk of bleeding with risk of is-
chaemic events. Eur J Haematol. 2015;94(suppl 77):23–29. doi: 10.1111/
ejh.12498
76. Sharma R, Flood VH. Advances in the diagnosis and treatment of von
Willebrand disease. Blood. 2017;130:2386–2391. doi: 10.1182/blood-2017
-05-782029
77. Franchini M, Coppola A. Atherothrombosis in von Willebrand disease: an ana-
lysis of the literature and implications for clinical management. Semin Thromb
Hemost. 2012;38:185–199. doi: 10.1055/s-0032-1301416
78. Boehnel C, Rickli H, Graf L, Maeder MT. Coronary angiography with or
without percutaneous coronary intervention in patients with hemophilia:
systematic review. Catheter Cardiovasc Interv. 2018;92:1–15. doi: 10.1002/
ccd.27255
79. Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A,
Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM. The bleeding score
predicts clinical outcomes and replacement therapy in adults with von
Willebrand disease. Blood. 2014;123:4037–4044. doi: 10.1182/blood-2014-
02-557264
80. Singh V, Patel NJ, Rodriguez AP, Shantha G, Arora S, Deshmukh A, Cohen MG,
Grines C, De Marchena E, Badheka A, Ghatak A. Percutaneous coronary inter-
vention in patients with end-stage liver disease. Am J Cardiol. 2016;117:
1729–1734. doi: 10.1016/j.amjcard.2016.03.010
81. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of
thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39–50. doi:
10.2147/HMER.S74612
82. Russo MW, Pierson J, Narang T, Montegudo A, Eskind L, Gulati S. Coronary ar-
tery stents and antiplatelet therapy in patients with cirrhosis. J Clin Gastroenterol.
2012;46:339–344. doi: 10.1097/MCG.0b013e3182371258
83. Maddur H, Bourdillon PD, Liangpunsakul S, Joseph Tector A, Fridell JA, Ghabril
M, Lacerda MA, Bourdillon C, Shen C, Kwo PY. Role of cardiac catheterization
and percutaneous coronary intervention in the preoperative assessment and
management of patients before orthotopic liver transplantation. Liver Transpl.
2014;20:664–672. doi: 10.1002/lt.23873
84. Patel NJ, Pau D, Nalluri N, Bhatt P, Thakkar B, Kanotra R, Agnihotri K, Ainani
N, Patel N, Patel N, Shah S, Kadavath S, Arora S, Sheikh A, Badheka AO,
Lafferty J, Alfonso C, Cohen M. Temporal trends, predictors, and outcomes of
in-hospital gastrointestinal bleeding associated with percutaneous coronary
intervention. Am J Cardiol. 2016;118:1150–1157. doi: 10.1016/j.amjcard.2016.
07.025
85. Krill T, Brown G, Weideman RA, Cipher DJ, Spechler SJ, Brilakis E, Feagins LA.
Patients with cirrhosis who have coronary artery disease treated with cardiac
stents have high rates of gastrointestinal bleeding, but no increased mortality.
Aliment Pharmacol Ther. 2017;46:183–192. doi: 10.1111/apt.14121
86. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the
Scientific and Standardization Committee of the International Society on
Thrombosis and Haemostasis. Definition of major bleeding in clinical investiga-
tions of antihemostatic medicinal products in non-surgical patients. J Thromb
Haemost. 2005;3:692–694. doi: 10.1111/j.1538-7836.2005.01204.x
87. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of
Anticoagulation. Definition of clinically relevant non-major bleeding in studies
of anticoagulants in atrial fibrillation and venous thromboembolic disease in
non-surgical patients: communication from the SSC of the ISTH. J Thromb
Haemost. 2015;13:2119–2126.
88. Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, Cho H, Ahn H, Cho YY,
Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Yoon JH.
Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepa-
titis B patients on antiviral treatment. Hepatology. 2017;66:1556–1569. doi:
10.1002/hep.29318
89. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL,
D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with
end-stage liver disease. Hepatology. 2001;33:464–470. doi: 10.1053/jhep.2001.
22172
90. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg.
1964;1:1–85.
91. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of
the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.
92. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, De
Belder MA, Kwok CS, Rashid M, Fischman DL, Mamas MA. Percutaneous cor-
onary intervention in cancer patients: a report of the prevalence and outcomes
in the United States [published online November 30, 2018]. Eur Heart J. doi:
10.1093/eurheartj/ehy769. https://academic.oup.com/eurheartj/advance-article-
abstract/doi/10.1093/eurheartj/ehy769/5221009?redirectedFrom=fulltext.
93. Ko DT, Yun L, Wijeysundera HC, Jackevicius CA, Rao SV, Austin PC, Marquis
JF, Tu JV. Incidence, predictors, and prognostic implications of hospitalization
for late bleeding after percutaneous coronary intervention for patients older
than 65 years. Circ Cardiovasc Interv. 2010;3:140–147. doi: 10.1161/CIRCINTER
VENTIONS.109.928721
94. Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE,
Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L,
Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong
PW, Ohman EM; TRILOGY ACS Investigators. Ascertainment, classification,
and impact of neoplasm detection during prolonged treatment with dual anti-
platelet therapy with prasugrel vs. clopidogrel following acute coronary syn-
drome. Eur Heart J. 2016;37:412–422. doi: 10.1093/eurheartj/ehv611
95. Fokkema ML, James SK, Albertsson P, Akerblom A, Calais F, Eriksson P, Jensen
J, Nilsson T, de Smet BJ, Sjo¨gren I, Thorvinger B, Lagerqvist B. Population trends
in percutaneous coronary intervention: 20-year results from the SCAAR
(Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol.
2013;61:1222–1230. doi: 10.1016/j.jacc.2013.01.007
96. Acharya T, Salisbury AC, Spertus JA, Kennedy KF, Bhullar A, Reddy HKK, Joshi
BK, Ambrose JA. In-hospital outcomes of percutaneous coronary intervention
in America’s safety net: insights from the NCDR Cath-PCI Registry. JACC
Cardiovasc Interv. 2017;10:1475–1485. doi: 10.1016/j.jcin.2017.05.042
97. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon
DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP,
Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD,
Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators.
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose
aspirin in individuals undergoing percutaneous coronary intervention for acute
coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet.
2010;376:1233–1243. doi: 10.1016/S0140-6736(10)61088-4
98. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow
J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
Storey RF, Harrington RA, Freij A, Thorse´n M; PLATO Investigators. Ticagrelor
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.
2009;361:1045–1057. doi: 10.1056/NEJMoa0904327
99. European Medicines Agency. Efient public assessment report: product informa-
tion. 2009. https://www.ema.europa.eu/documents/product-information/efient-
epar-product-information_en.pdf. Accessed 25 October 2018.
100. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J,
Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR,
Becker RC; PLATO Study Group. Ticagrelor versus clopidogrel in patients with
acute coronary syndromes and a history of stroke or transient ischemic attack.
Circulation. 2012;125:2914–2921. doi: 10.1161/CIRCULATIONAHA.111.082727
101. Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ,
Murphy SA, Scirica BM, Braunwald E, Thrombin Receptor Antagonist in
Secondary Prevention of Atherothrombotic Ischemic Events TSC and
Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic
stroke. Stroke. 2013;44:691–698.
102. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X,
Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC;
CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or tran-
sient ischemic attack. N Engl J Med. 2013;369:11–19. doi: 10.1056/
NEJMoa1215340
103. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held
P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS; SOCRATES
Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke
or transient ischemic attack. N Engl J Med. 2016;375:35–43. doi:
10.1056/NEJMoa1603060
104. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS,
Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological
Emergencies Treatment Trials Network, and the POINT Investigators.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J
Med. 2018;379:215–225. doi: 10.1056/NEJMoa1800410
105. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys
D, Matias-Guiu J, Rupprecht HJ; MATCH Investigators. Aspirin and clopidogrel
compared with clopidogrel alone after recent ischaemic stroke or transient is-
chaemic attack in high-risk patients (MATCH): randomised, double-blind, pla-
cebo-controlled trial. Lancet. 2004;364:331–337. doi: 10.1016/S0140-6736
(04)16721-4
106. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y,
Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L,
20 Urban et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Dahlo¨f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K,
Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P,
Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study
Group. Aspirin and extended-release dipyridamole versus clopidogrel for re-
current stroke. N Engl J Med. 2008;359:1238–1251. doi: 10.1056/NEJM
oa0805002
107. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA.
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N
Engl J Med. 2012;367:817–825.
108. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker
K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-
Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV,
Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines
for the early management of patients with acute ischemic stroke: a guideline for
healthcare professionals from the American Heart Association/American
Stroke Association. Stroke. 2018;49:e46–e110. doi: 10.1161/STR.000000000
0000158
109. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz
MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ,
Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; American
Heart Association Stroke Council, Council on Cardiovascular and Stroke
Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular
Disease. Guidelines for the prevention of stroke in patients with stroke and
transient ischemic attack: a guideline for healthcare professionals from the
American Heart Association/American Stroke Association. Stroke. 2014;45:
2160–2236. doi: 10.1161/STR.0000000000000024
110. Derdeyn CP, Zipfel GJ, Albuquerque FC, Cooke DL, Feldmann E, Sheehan JP,
Torner JC; American Heart Association Stroke Council. Management of brain
arteriovenous malformations: a scientific statement for healthcare professionals
from the American Heart Association/American Stroke Association. Stroke.
2017;48:e200–e224. doi: 10.1161/STR.0000000000000134
111. Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL; MARS
Coinvestigators. Untreated brain arteriovenous malformation: patient-level
meta-analysis of hemorrhage predictors. Neurology. 2014;83:590–597. doi:
10.1212/WNL.0000000000000688
112. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi
Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA,
Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K,
Libman R, Barreau X, Moskowitz AJ; International ARUBA Investigators.
Medical management with or without interventional therapy for unruptured
brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, rand-
omised trial. Lancet. 2014;383:614–621. doi: 10.1016/S0140-6736(13)62302-8
113. Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients
with coronary artery disease requiring cardiac and noncardiac surgery.
Circulation. 2013;128:2785–2798. doi: 10.1161/CIRCULATIONAHA.113.003675
114. Banerjee S, Angiolillo DJ, Boden WE, Murphy JG, Khalili H, Hasan AA,
Harrington RA, Rao SV. Use of antiplatelet therapy/DAPT for post-PCI patients
undergoing noncardiac surgery. J Am Coll Cardiol. 2017;69:1861–1870. doi:
10.1016/j.jacc.2017.02.012
115. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A,
Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson
A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni
M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom
J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O,
Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R,
Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S; POISE-
2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med.
2014;370:1494–1503. doi: 10.1056/NEJMoa1401105
116. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD, Ford I,
Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B,
Kjeldsen KP, Longrois D, Lu¨scher TF, Pierard L, Pocock S, Price S, Roffi M,
Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C; Task Force Members.
2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment
and management: the Joint Task Force on non-cardiac surgery: cardiovascular
assessment and management of the European Society of Cardiology (ESC) and
the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:
2383–2431. doi: 10.1093/eurheartj/ehu282
117. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB,
Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT,
Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update
on duration of dual antiplatelet therapy in patients with coronary artery disease:
a report of the American College of Cardiology/American Heart Association
Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:
1082–1115. doi: 10.1016/j.jacc.2016.03.513
118. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabro` P,
Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA,
Saia F, Valgimigli M, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M,
Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society
of Interventional Cardiology (SICI-GISE); Italian Society for the Study of
Haemostasis and Thrombosis (SISET); Italian Society of Anesthesia and
Intensive Care Medicine (SIAARTI); Italian Society of Surgery (SIC); Italian
Society for Cardiac Surgery (SICCH); Italian Society of Vascular and
Endovascular Surgery (SICVE); Italian Society of Urology (SIU); Italian
Orthopaedic Society (SIOT); Italian Society of Thoracic Surgeons (SICT); Italian
Federation of Scientific Societies of Digestive System Diseases (FISMAD); Italian
Society of Digestive Endoscopy (SIED); Italian Association of Hospital
Gastroenterology and Digestive Endoscopy (AIGO); Italian Association of
Gastroenterology and Digestive Endoscopy (SIGE); Italian Society of
Maxillofacial Surgery (SICMF); Italian Society of Reconstructive Plastic Surgery
and Aesthetics (SICPRE); Italian Society of Gynecology and Obstetrics (SIGO);
Italian Society of Neurosurgery (SINch); Italian Association of Hospital
Pulmonologist (AIPO); Italian Society of Periodontology (SIdP); Italian Society
of Ophthalmology (SOI); Italian Association of Hospital Otorhinolaryngologist
(AOOI); Italian Association of Hospital Surgeons (ACOI); Association of
Obstetricians Gynecologists Italian Hospital (AOGOI). A multidisciplinary ap-
proach on the perioperative antithrombotic management of patients with
coronary stents undergoing surgery: surgery after stenting 2. JACC Cardiovasc
Interv. 2018;11:417–434. doi: 10.1016/j.jcin.2017.10.051
119. Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S,
Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P,
Collet JP; French Working Group on Perioperative Hemostasis (GIHP).
Management of antiplatelet therapy in patients undergoing elective invasive
procedures: proposals from the French Working Group on Perioperative
Hemostasis (GIHP) and the French Study Group on Thrombosis and
Hemostasis (GFHT): in collaboration with the French Society for Anesthesia
and Intensive Care (SFAR). Arch Cardiovasc Dis. 2018;111:210–223. doi:
10.1016/j.acvd.2017.12.004
120. Vivas D, Roldan I, Ferrandis R, Marin F, Roldan V, Tello-Montoliu A, Ruiz-
Nodar JM, Gomez-Doblas JJ, Martin A, Llau JV, Ramos-Gallo MJ, Munoz R,
Arcelus JI, Leyva F, Alberca F, Oliva R, Gomez AM, Montero C, Arikan F, Ley L,
Santos-Bueso E, Figuero E, Bujaldon A, Urbano J, Otero R, Hermida JF,
Egocheaga I, Llisterri JL, Lobos JM, Serrano A, Madridano O, Ferreiro JL.
Perioperative and periprocedural management of antithrombotic therapy: con-
sensus document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD,
SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES,
SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Rev Esp Cardiol (Engl Ed).
2018;71:553–564.
121. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N,
Ju¨ni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B,
Windecker S, Serruys PW. Early and late coronary stent thrombosis of
sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data
from a large two-institutional cohort study. Lancet. 2007;369:667–678. doi:
10.1016/S0140-6736(07)60314-6
122. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H,
Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y,
Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M,
Kita T, Mitsudo K; j-Cypher Registry Investigators. Antiplatelet therapy and
stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;
119:987–995. doi: 10.1161/CIRCULATIONAHA.108.808311
123. Steely AM, Callas PW, Neal D, Scali ST, Goodney PP, Schanzer A, Cronenwett
JL, Bertges DJ; Vascular Quality Initiative. Regional variation in postoperative
myocardial infarction in patients undergoing vascular surgery in the United
States. Ann Vasc Surg. 2017;40:63–73. doi: 10.1016/j.avsg.2016.07.099
124. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal safety of OTC
analgesics. J Cardiovasc Pharmacol Ther. 2018;23:103–118. doi: 10.1177/1074
248417751070
125. Singh G. Gastrointestinal complications of prescription and over-the-counter
nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database:
Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;
7:115–121.
126. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A.
Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-
inflammatory drugs. Gastroenterology. 2018;154:500–514. doi: 10.1053/j.gastro
.2017.10.049
127. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the
American College of Gastroenterology. Guidelines for prevention of NSAID-
related ulcer complications. Am J Gastroenterol. 2009;104:728–738. doi:
10.1038/ajg.2009.115
ARC-Defined High Bleeding Risk in PCI Patients 21
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..128. Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ,
Herings R, Gini R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Kuipers EJ, van
der Lei J, Sturkenboom MC. Risk of upper gastrointestinal bleeding from differ-
ent drug combinations. Gastroenterology. 2014;147:784–792.e9; quiz e13. doi:
10.1053/j.gastro.2014.06.007
129. Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL,
Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH.
Gastrointestinal safety of celecoxib versus naproxen in patients with cardio-
thrombotic diseases and arthritis after upper gastrointestinal bleeding
(CONCERN): an industry-independent, double-blind, double-dummy, rando-
mised trial. Lancet. 2017;389:2375–2382. doi: 10.1016/S0140-6736(17)30981-9
130. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R,
Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith
JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroi-
dal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the
CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis
Safety Study. JAMA. 2000;284:1247–1255.
131. Aguayo GA, Donneau AF, Vaillant MT, Schritz A, Franco OH, Stranges S,
Malisoux L, Guillaume M, Witte DR. Agreement between 35 published frailty
scores in the general population. Am J Epidemiol. 2017;186:420–434. doi:
10.1093/aje/kwx061
132. Dodson JA, Hochman JS, Roe MT, Chen AY, Chaudhry SI, Katz S, Zhong H,
Radford MJ, Udell JA, Bagai A, Fonarow GC, Gulati M, Enriquez JR, Garratt KN,
Alexander KP. The association of frailty with in-hospital bleeding among older
adults with acute myocardial infarction: insights from the ACTION Registry.
JACC Cardiovasc Interv. 2018;11:2287–2296. doi: 10.1016/j.jcin.2018.08.028
133. Numasawa Y, Kohsaka S, Ueda I, Miyata H, Sawano M, Kawamura A, Noma S,
Suzuki M, Nakagawa S, Momiyama Y, Fukuda K. Incidence and predictors of
bleeding complications after percutaneous coronary intervention. J Cardiol.
2017;69:272–279. doi: 10.1016/j.jjcc.2016.05.003
134. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa
K, Nishikawa M, Miyazaki S, Nakamura M. Efficacy and safety of adjusted-dose
prasugrel compared with clopidogrel in Japanese patients with acute coronary
syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684–1692.
135. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, Kawamura
A, Fukuda K, Roe MT, Rumsfeld JS, JCD-KiCS and NCDR. An international
comparison of patients undergoing percutaneous coronary intervention: a
collaborative study of the National Cardiovascular Data Registry (NCDR) and
Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-
KiCS). Am Heart J. 2015;170:1077–1085.
136. Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A,
Feres F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice
MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS. Racial differences in
ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient
level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019;119:
149–162. doi: 10.1055/s-0038-1676545
137. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso
SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prog-
nostic impact, and influence of antithrombotic therapy on access and nonaccess
site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv.
2011;4:191–197. doi: 10.1016/j.jcin.2010.10.011
138. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP,
Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey
RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopi-
dogrel in patients with ST-elevation acute coronary syndromes intended for
reperfusion with primary percutaneous coronary intervention: a Platelet
Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation.
2010;122:2131–2141. doi: 10.1161/CIRCULATIONAHA.109.927582
139. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe
CH, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel compared with clo-
pidogrel in patients undergoing percutaneous coronary intervention for ST-
elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised
controlled trial. Lancet. 2009;373:723–731. doi: 10.1016/S0140-6736
(09)60441-4
140. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD,
Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R,
Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM,
Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual anti-
platelet treatment and cardiac events after percutaneous coronary intervention
(PARIS): 2 year results from a prospective observational study. Lancet. 2013;
382:1714–1722. doi: 10.1016/S0140-6736(13)61720-1
22 Urban et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz372/5492739 by London School of H
ygiene & Tropical M
edicine user on 05 July 2019
